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This is an updated version of the original Cochrane Review, published in 2016, Issue 7.
Sudden Unexpected Death in Epilepsy (SUDEP) is defined as sudden, unexpected, witnessed or unwitnessed, non-
traumatic or non-drowning death of people with epilepsy, with or without evidence of a seizure, excluding
documented status epilepticus and in whom postmortem examination does not reveal a structural or
toxicological cause for death. SUDEP has a reported incidence of 1 to 2 per 1000 patient-years and represents
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the most common epilepsy-related cause of death. The presence and frequency of generalised tonic-clonic
seizures (GTCS), male sex, early age of seizure onset, duration of epilepsy, and polytherapy are all predictors of
risk of SUDEP. The exact pathophysiology of SUDEP is currently unknown, although GTCS-induced cardiac,
respiratory, and brainstem dysfunction appears likely. Appropriately chosen antiepileptic drug treatment can
render around 70% of patients free of all seizures. However, around one-third will remain drug-resistant despite
polytherapy. Continuing seizures place patients at risk of SUDEP, depression, and reduced quality of life.
Preventative strategies for SUDEP include reducing the occurrence of GTCS by timely referral for presurgical
evaluation in people with lesional epilepsy and advice on lifestyle measures; detecting cardiorespiratory distress
through clinical observation and seizure, respiratory, and heart rate monitoring devices; preventing airway
obstruction through nocturnal supervision and safety pillows; reducing central hypoventilation through physical
stimulation and enhancing serotonergic mechanisms of respiratory regulation using selective serotonin reuptake
inhibitors (SSRIs); and reducing adenosine and endogenous opioid-induced brain and brainstem depression.
Objectives
To assess the effectiveness of interventions in preventing SUDEP in people with epilepsy by synthesising evidence
from randomised controlled trials of interventions and cohort and case-control non-randomised studies.
Search methods
For the latest update we searched the following databases without language restrictions: Cochrane Register of
Studies (CRS Web, 4 February 2019); MEDLINE (Ovid, 1946 to 1 February 2019); SCOPUS (1823 to 4 February
2019); PsycINFO (EBSCOhost, 1887 to 4 January 2019); CINAHL Plus (EBSCOhost, 1937 to 4 February 2019);
ClinicalTrials.gov (5 February 2019); and the World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP, 5 February 2019). We checked the reference lists of retrieved studies for additional
reports of relevant studies and contacted lead study authors for any relevant unpublished material. We identified
any grey literature studies published in the last five years by searching: Zetoc database; ISI Proceedings;
International Bureau for Epilepsy (IBE) congress proceedings database; International League Against Epilepsy
(ILAE) congress proceedings database; abstract books of symposia and congresses, meeting abstracts, and
research reports.
Selection criteria
We aimed to include randomised controlled trials (RCTs), quasi-RCTs, and cluster-RCTs; prospective non-
randomised cohort controlled and uncontrolled studies; and case-control studies of adults and children with
epilepsy receiving an intervention for the prevention of SUDEP. Types of interventions included: early versus
delayed pre-surgical evaluation for lesional epilepsy; educational programmes; seizure-monitoring devices;
safety pillows; nocturnal supervision; selective serotonin reuptake inhibitors (SSRIs); opiate antagonists; and
adenosine antagonists.
Data collection and analysis
We aimed to collect data on study design factors and participant demographics for included studies. The primary
outcome of interest was the number of deaths from SUDEP. Secondary outcomes included: number of other
deaths (unrelated to SUDEP); change in mean depression and anxiety scores (as defined within the study);
clinically important change in quality of life, that is any change in quality of life score (average and endpoint)
according to validated quality of life scales; and number of hospital attendances for seizures.
Main results
We identified 1277 records from the databases and search strategies. We found 10 further records by searching
other resources (handsearching). We removed 469 duplicate records and screened 818 records (title and
abstract) for inclusion in the review. We excluded 785 records based on the title and abstract and assessed 33
full-text articles. We excluded 29 studies: eight studies did not assess interventions to prevent SUDEP; eight
studies were review articles, not clinical studies; five studies measured sensitivity of devices to detect GTCS but
did not directly measure SUDEP; six studies assessed risk factors for SUDEP but not interventions for preventing
SUDEP; and two studies did not have a control group.
We included one cohort study and three case-control studies of serious to critical risk of bias. The 6-month
prospective cohort study observed no significant effect of providing patients with SUDEP information on drug
compliance and quality of life, anxiety and depression levels. The study was too short and with no deaths
observed in either group to determine a protective effect. Two case control studies reported a protective effect
for nocturnal supervision against SUDEP. However due to significant heterogeneity, the results could not be
combined in meta-analysis. One study of 154 SUDEP cases and 616 controls reported an unadjusted odds ratio
(OR) of 0.34 (95% CI 0.22 to 0.53; P < 0.0001). The same study demonstrated the protective effect was
independent of seizure control, suggesting that nocturnal supervision is not just a surrogate marker of seizure
control. The second case-control study of 48 SUDEP cases and 220 controls reported an unadjusted OR of 0.08
(95% CI 0.02 to 0.27; P < 0.0001). The third case-control study of residential care centre patients who were
already receiving physical checks more than 15 minutes apart throughout the night did not report any protective
effect for additional nocturnal supervision (physical checks < 15 minutes apart; use of listening devices;
dormitory setting; and use of bed sensors). However the same study did ascertain a difference between centres:
the residential centre with the lowest level of supervision had the highest incidence of SUDEP. The case-control
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studies did not report on quality of life or depression and anxiety scores.
Authors' conclusions
We found limited, very low-certainty evidence that supervision at night reduces the incidence of SUDEP. Further
research is required to identify the effectiveness of other current interventions — for example seizure detection
devices, safety pillows, SSRIs, early surgical evaluation, educational programmes, and opiate and adenosine
antagonists — in preventing SUDEP in people with epilepsy.
Plain language summary
Treatments to prevent Sudden Unexpected Death in Epilepsy (SUDEP)
Background
Sudden Unexpected Death in Epilepsy (SUDEP) is defined as sudden, unexpected, witnessed or unwitnessed, non-
traumatic or non-drowning death of people with epilepsy, with or without evidence of an epileptic seizure, and
for whom a postmortem examination reveals no other cause of death. SUDEP is the most common epilepsy-
related cause of death, with around 1 to 2 deaths per 1000 patients per year. Frequent seizures, in particular
convulsive seizures (termed generalised tonic clonic seizures (GTCS)) , male gender, young age of first seizure,
long duration of epilepsy, and taking multiple antiepileptic drugs are all thought to increase the risk for SUDEP;
exactly why SUDEP occurs is currently unknown, however, though it is thought to be related to heart failure,
breathing difficulties, and brain damage following GTCS.
With the correct antiepileptic treatment regimen around 70% of people with epilepsy can become free of all
seizures. However, around one-third of people with epilepsy will continue to have seizures despite taking
multiple antiepileptic drugs. Continuing seizures place patients at risk of SUDEP and can be associated with
depression and lower quality of life. Strategies to try to prevent SUDEP include reducing the number of GTCS a
patient has (by considering epilepsy surgery or making lifestyle changes), examining for heart and breathing
problems during and following seizures, supervising patients at night or using safety pillows to prevent
breathing difficulties. Drugs that increase the brain chemical serotonin and reduce the brain chemicals adenosine
and opioids may also help prevent breathing difficulties.
Objective
To examine the effectiveness of treatments designed to prevent SUDEP.
Methods
We searched electronic databases and contacted experts in the area to find relevant randomised or non-
randomised (observational) studies for the review. Outcomes of interest were: number of deaths due to SUDEP;
number of other deaths not related to SUDEP; changes in anxiety, depression, and quality of life; and number of
hospital attendances.
The evidence is current to February 2019.
Results
Out of 818 records found in our searches, we were able to include four observational studies. We found several
studies that measured how sensitive devices are at detecting GTCS at night, but these studies did not measure
SUDEP and so weren't relevant to this review.
Three studies investigated whether having a supervising person sharing a bedroom with the patient and using
special precautions such as regular checking throughout the night or a listening device prevented SUDEP. Two of
the three studies which included 202 people who had died of SUDEP and 836 people with epilepsy who were alive
found these measures did prevent SUDEP. The third study of 60 SUDEP deaths and 240 controls looked at
whether increasing night-time supervision for patients in two residential units above regular checks to include
bed monitors and listening devices prevented SUDEP. This study did not show any additional preventative effect.
However the same study did show that the centre with the most SUDEP deaths had the lowest level of
supervision. The studies did not report on changes in anxiety, depression, quality of life and number of hospital
attendances.
The fourth study looked at the effect of giving information to people with epilepsy about SUDEP and whether it
improved the taking of antiepileptic medication and the impact on mood and anxiety. The study followed
patients up for six months after being given the information (or not) and did not demonstrate any effect on the
taking of medication or mood and anxiety. There were no deaths in the study so the effect of giving information
and impact on risk of SUDEP is unknown.
Certainty of the evidence
We judged the certainty of the evidence from this review to be very low as the included studies were not
randomised, and information about supervision measures to prevent SUDEP was not available in up to 40% of the
people within the studies who did not experience SUDEP.
Conclusions
We found limited, very low-certainty evidence that supervision at night prevents SUDEP. Further research is
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needed to identify if other treatments, such as seizure detection devices, safety pillows, and drug interventions
working on serotonin, adenosine, and opiate levels in the brain are effective in preventing SUDEP in people with
epilepsy.
Background 
This is an updated version of the original Cochrane Review, published in the Cochrane Database of
Systematic Reviews (2016, Issue 7; Maguire 2016).
Description of the condition
Sudden Unexpected Death in Epilepsy (SUDEP) is defined as sudden, unexpected, witnessed or unwitnessed, non-
traumatic or non-drowning death of people with epilepsy, with or without evidence of a seizure, excluding
documented status epilepticus, and in whom postmortem examination does not reveal a structural or
toxicological cause for death.
SUDEP has a reported incidence of 1 to 2 per 1000 patient-years and represents the most common
epilepsy-related cause of death (Shorvon 2011). Other deaths related to epilepsy include non-recovery
from status epilepticus, seizure-related accidents, and suicide. SUDEP claims the lives of young adults,
causing devastation to families. Its prevention is of paramount importance. Discussions around SUDEP are
often difficult for patients and health professionals, although patients should be given and have access to
information on SUDEP. Evidence from a UK-based study suggests that SUDEP is not commonly discussed
with patients and families (Morton 2006). The highest SUDEP incidence reported in patients undergoing
presurgical evaluation or having previously failed surgery was 9.3 per 1000 patient-years (Dasheiff 1991
). A pooled meta-analysis of four case-control studies ascertained that the presence and frequency of
generalised tonic-clonic seizures (GTCS) was the strongest predictor of risk of SUDEP. For example,
compared with patients with no GTCS, patients having three or more GTCS per month had an odds
ratio greater than 15. Male gender, age of onset of epilepsy of under 16 years old, duration of epilepsy
for over 15 years, and polytherapy are also significant predictors of risk for SUDEP (Hesdorffer 2011; Hesdorffer
2012).
The exact pathophysiology of SUDEP is currently unknown, although GTCS-induced cardiac, respiratory,
and brainstem dysfunction appears likely (Langan 2000).
Information has been gleaned from rare monitored cases of SUDEP, and demonstrates severe postictal
electroencephalogram (EEG) suppression.
In the retrospective Mortality in Epilepsy Monitoring Unit Study (MORTEMUS) of 16 SUDEP cases and nine
near-SUDEP cases, available cardiorespiratory data were analysed in 10 monitored cases of SUDEP. The
study ascertained a consistent pattern of changes that initially began with rapid breathing (18 to 50
breaths per minute) immediately following a GTCS and followed within three minutes by postictal
generalised EEG suppression, terminal apnoea, and severe bradycardia with subsequent cardiac arrest. In
this study the cardiorespiratory collapse was terminal in one-third of patients. In the remaining two-thirds,
there appeared to be a transient restoration of cardiac function but with abnormal respiratory effort
potentially aggravated by the prone position, leading eventually to terminal apnoea and terminal asystole.
There were less consistent patterns of cardiorespiratory change in five of nine monitored near-SUDEP
cases. In these cases, postictal apnoea followed by asystole, ictal asystole, ventricular fibrillation, and
postictal cardiorespiratory arrest were observed. The study highlighted a potential window for lifesaving
intervention, in that those patients who received cardiopulmonary resuscitation within three minutes (seven
near-SUDEP cases) were successfully resuscitated. The study suggested improved supervision within
epilepsy-monitoring units, particularly nocturnal supervision (Ryvlin 2013a).
Ictal hypoxia, dysfunction in subcortical and brainstem networks controlling electrogenesis, and the
release of adenosine and endogenous opioids within the brain and brainstem following a GTCS have been
proposed as mechanisms to explain the above clinical findings (Nashef 2009). Seizure-related
arrhythmias were originally proposed as a mechanism for SUDEP, but many believe this to be a self-
limiting process (Schuele 2010). There are, however, cases of death of patients exhibiting rare sodium and
potassium channelopathies, although the exact circumstances of death are uncertain (Tu 2011).
Appropriately chosen antiepileptic drug treatment can render around 70% of people with epilepsy free of all
seizures. However, around one-third of people with epilepsy will remain drug-resistant despite polytherapy.
Continuing seizures place patients at risk of SUDEP, depression, and reduced quality of life. Preventative
strategies for SUDEP are therefore of paramount importance.
Description of the intervention
Experts within the field of SUDEP believe it results from a multifactorial neurovegetative breakdown. Thus
any preventative intervention must target contributing factors (Ryvlin 2013b). These include:
reducing the occurrence of GTCS by timely referral for presurgical evaluation in people with lesional epilepsy1.
and advice on lifestyle measures (e.g. concordance with optimal antiepileptic drug treatment);
enhancing the ability to detect cardiorespiratory distress through clinical observation and seizure, respiratory,2.
and heart rate monitoring devices;
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preventing airway obstruction through nocturnal supervision and safety pillows;3.
reducing central hypoventilation through physical stimulation and enhancing serotonergic mechanisms of4.
respiratory regulation using selective serotonin reuptake inhibitors (SSRIs);
reducing adenosine and endogenous opioid-induced brain and brainstem depression.5.
How the intervention might work
Patients with a surgical epileptogenic target should be referred for presurgical evaluation since targeted1.
surgery may improve the likelihood of successful seizure control. Whilst studies report a greater risk of
SUDEP in patients who have failed surgery, it is unclear whether the surgery itself is preventative for
SUDEP or whether risk differences relate to the underlying pathologic process (Ryvlin 2006). Patient education
is important in ensuring compliance with treatment and should include discussion of lifestyle factors that may
adversely affect seizure control and drug effectiveness (e.g. sleep deprivation, stress, and excess alcohol).
Similarly a care plan for seizure clusters and discussions around contraception, pregnancy, gastrointestinal
disorders, and any other medications that may affect antiepileptic drug treatment are all important discussion
points. This may be delivered through formal educational programmes, advice leaflets, or verbal consultation.
Seizure-monitoring devices, which include bed sensors, fall alarms, and tracking devices, range from2.
technology worn at the wrist that detects seizures via changes in vibrations to more sophisticated multimodal
systems monitoring movements and vital signs, including heart rate, via a sensitive bed mat. These systems
alert a carer or parent to potential seizure activity, which in turn may prevent SUDEP.
Safety pillows, which have small holes, are thought to reduce postictal respiratory distress and thus3.
SUDEP when the person is face down on the pillow in a prone position (Devinsky 2012). One
retrospective study reported that around 71% of people who died of SUDEP were in the prone position,
suggesting position may play a significant role in the condition (Kloster 1999). People in postictal hypoxic
coma will not be able to correct their position and are thus at risk of respiratory failure. The utility of
oxygen therapy following a seizure is used in most epilepsy monitoring units and has been shown to
prevent SUDEP in a mouse model of seizure-induced SUDEP by reducing the risk of respiratory distress (Venit
2004).
Nocturnal supervision would allow turning of the person from a prone to a recovery position, reducing4.
the risk of respiratory distress and reducing central hypoventilation. One case-control study found that
nocturnal supervision was protective against SUDEP (Langan 2005). Serotonergic nuclei within the
lower brainstem play an important role in regulating respiratory function, particularly in the context of
recurrent hypoxia. Abnormalities of these nuclei are documented in sudden infant death and also in
mice models of SUDEP (Uteshev 2010). The SSRI fluoxetine has been shown to prevent apnoea in these
mice models. A clinical retrospective study ascertained that people undergoing videotelemetry and
taking an SSRI were significantly less likely to have ictal/postictal hypoxia than those not taking an
SSRI (Bateman 2010). Another study observed the effect of peri-ictal nursing interventions (supplemental
oxygen, oropharyngeal suction, and patient repositioning) on respiratory dysfunction and postictal EEG
suppression. It showed a reduced duration of hypoxaemia and EEG suppression with early peri-ictal
interventions (Seyal 2013).
Inhibitors of adenosine and opiate substances may prevent SUDEP by reducing the severity of postictal EEG5.
depression and brainstem dysfunction. Caffeine, an antagonist of adenosine receptors, is potentially pro-
convulsant. However naloxone, an opiate receptor antagonist, has not been demonstrated to have a pro-
convulsant effect and thus may have a use in preventing SUDEP.
Why it is important to do this review
SUDEP has devastating consequences for patients and families. Various devices and interventions are available to
people with epilepsy that are thought to reduce the risk of SUDEP. However, no robust evidence is available to
confirm this preventative effect. A systematic review of the literature base will inform patients and healthcare
professionals on treatment policy and prevention of SUDEP.
Objectives 
To assess the effectiveness of interventions in preventing SUDEP in people with epilepsy by synthesising evidence
from randomised controlled trials of interventions and cohort and case-control non-randomised studies.
Methods 
Criteria for considering studies for this review 
Types of studies 
We considered the following types of studies for inclusion.
Randomised controlled trials (RCTs), quasi-RCTs, and cluster-RCTs1.
Prospective non-randomised cohort controlled and uncontrolled studies2.
Case-control studies3.
The rationale for including non-randomised studies was that given the relatively low incidence rate of SUDEP, an
RCT would need to recruit a very large sample in order to show evidence of a preventative effect. Non-
randomised studies, including case-control designs, are better at addressing the question of effectiveness in
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SUDEP prevention given their ability to include larger populations for longer treatment periods.
Types of participants 
We included participants who satisfied each of the following criteria.
Any age1.
Diagnosis of epilepsy (any type)2.
Receiving an intervention for prevention of SUDEP3.
Types of interventions 








Intervention group: patients who received an intervention in preventing SUDEP.
Control group(s): patients who received a placebo, comparative intervention, or no intervention in preventing
SUDEP.
Types of outcome measures 
Primary outcomes
Number of deaths from SUDEP1.
Secondary outcomes
Number of other deaths (unrelated to SUDEP)1.
Change in mean depression and anxiety scores (as defined within the study)2.
Clinically important change in quality of life: any change in quality of life score (average and endpoint)3.
according to validated quality of life scales
Number of hospital attendances for seizures4.
Search methods for identification of studies 
Electronic searches 
Searches were run for the original review on 16 December 2014 and subsequent searches were run in November
2015, September 2017, and February 2019. For the latest update we searched the following databases.
Cochrane Register of Studies (CRS Web, 4 February 2019), using the search strategy shown in Appendix 1.1.
MEDLINE (Ovid, 1946 to 1 February 2019), using the search strategy shown in Appendix 2.2.
SCOPUS (1823 to 4 February 2019), using the search strategy shown in Appendix 3.3.
PsycINFO (EBSCOhost, 1887 to 4 February 2019), using the search strategy shown in Appendix 4.4.
CINAHL Plus (EBSCOhost, 1937 to 4 February 2019), using the search strategy shown in Appendix 5.5.
ClinicalTrials.gov (5 February 2019), using the search strategy shown in Appendix 6.6.
World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP, 5 January 2019), using7.
the search strategy shown in Appendix 7.
The Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials
(CENTRAL) are both now included in the Cochrane Register of Studies (CRS Web). We used no language
restrictions.
Searching other resources 
We checked the reference lists of retrieved studies for additional reports of relevant studies. We also contacted
lead study authors for any relevant unpublished material or missing data from included studies. We identified
duplicate studies by screening reports according to title, authors' names, location, and medical institute, omitting
any duplicated studies.
We identified any grey literature studies published in the last five years by searching:
Zetoc database;1.
ISI Proceedings;2.
International Bureau for Epilepsy (IBE) congress proceedings database;3.
International League Against Epilepsy (ILAE) congress proceedings database;4.
Abstract books of symposia and congresses, meeting abstracts, and research reports.5.
Data collection and analysis 
Selection of studies 
Two review authors (CFJ, MJM) reviewed the titles and abstracts of the studies identified by the electronic
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searches and removed studies that did not meet the inclusion criteria. The same two review authors then
reviewed the full-text reports to determine eligibility. We discussed any disagreements, consulting a third review
author (SJN) if necessary. In the event of multiple reports deriving from one study, we linked the reports together.
Data extraction and management 
Two review authors (MJM, SJN) independently completed data extraction using a pre-standardised data extraction
form for the included studies.
We extracted the following information.
Methods
Year of publication1.
Number of study centres2.
Language3.
Industry funding4.
Study design (RCT, prospective cohort study, case-control study)5.
Blinding6.




Dose range of drug intervention11.
Inclusion and exclusion criteria12.
Participants
Age range1.
Number of male/female participants2.
Duration of epilepsy3.
Mean age of onset of epilepsy4.
Current number of antiepileptic drugs (AEDs)5.
Epilepsy type (focal, generalised, unclassified)6.
Seizure types (GTCS, focal onset seizures)7.
Baseline mean depression score or severity8.
Baseline mean seizure frequency/month9.
Outcomes
Number of participants experiencing each outcome recorded per treatment group1.
Number of dropouts2.
Assessment of risk of bias in included studies
Two review authors (SJN, MJM) independently assessed the risk of bias for the included studies.
Due to the observational design, we assessed risk of bias for non-randomised studies using the ROBINS-I
tool (Sterne 2016). This tool considers seven domains of bias: two domains of bias pre-intervention (bias due to
confounding and bias in selection of participants into the study); one domain of bias at intervention (bias in the
measurement of interventions); and four domains of bias post intervention (bias due to departures from intended
interventions, bias due to missing data, bias in measurement of outcomes, and bias in selection of the reported
result). We planned to perform a separate 'Risk of bias' assessment for each outcome of interest in the study.
Important confounders of interest in this Cochrane Review included:
proportion of males;1.
proportion of participants with generalised seizures;2.
mean age of onset of epilepsy;3.
mean duration of epilepsy;4.
epilepsy type;5.
mean concomitant AEDs;6.
baseline seizure frequency (including baseline GTCS frequency);7.
baseline depression score.8.
Each domain of bias contained signalling questions to facilitate judgements of risk of bias. The response options
for the signalling questions were: yes; probably yes; probably no; no; and no information. We have specified the
signalling questions for each domain in Appendix 8.
The 'Risk of bias' judgement options for each domain were:
low risk of bias: the study is comparable to a well-performed randomised trial with regard to this domain;1.
moderate risk of bias: the study is sound for a non-randomised study with regard to this domain but cannot2.
be considered comparable to a well-performed randomised trial;
serious risk of bias: the study has some important problems in this domain;3.
critical risk of bias: the study is too problematic in this domain to provide any useful evidence on the effects of4.
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intervention;
no information on which to base a judgement about risk of bias for this domain.5.
We have presented guidance for an overall risk of bias for a study based on outcomes from 'Risk of bias'
judgements of each domain in Table 1.
We would have examined all domains of the current Cochrane 'Risk of bias' assessment tool for RCTs (Higgins
2011). We would have made an overall summary judgement of risk of bias for each study per outcome, followed
by an overall judgement per outcome across studies.
We planned to incorporate the 'Risk of bias' judgement into the analysis by performing a sensitivity analysis
including only studies rated as being at low risk of bias. We will perform such an analysis in future updates if
additional studies are included in the review.
Measures of treatment effect
For binary outcomes (number of SUDEP deaths, number of non-SUDEP deaths, number of hospital attendances)
we planned to present results as risk ratios with 95% confidence intervals (CIs) for RCTs and non-randomised
cohort studies, and odds ratios with 95% CIs for case-control studies.
For continuous outcomes (mean change in depression score, mean change in quality of life score) we planned to
present results as mean differences or standardised mean differences with 95% CIs.
Unit of analysis issues 
There were no unit of analysis issues in any of the included studies. In the event of unit of analysis issues
occurring across the included studies in future updates (e.g. cluster randomised or repeated measures), we
would:
determine whether the methods in such studies were conducted appropriately;1.
combine extracted effect sizes from such studies through a generic inverse variance meta-analysis.2.
Dealing with missing data
For future updates of the review, we intend to search for missing statistics from studies by contacting the study
authors. In the event of the data being unavailable, we will attempt to determine whether or not the data are
missing at random and the possible impact of missing data on analysis.
Assessment of heterogeneity 
We did not perform meta-analysis in the review due to the heterogeneity in the reporting of results in two of the
included studies.
If we are able to perform meta-analysis in future updates of the review, we will assess clinical heterogeneity by
comparing the distribution of important participant factors between studies (age, proportion of males,
proportion with generalised seizures, epilepsy type, duration of epilepsy, mean concomitant AEDs, baseline
seizure frequency, baseline depression score) and trial factors (study design, type of control group). We will
assess statistical heterogeneity by using the I² statistic, with an I² value equal to or greater than 75% indicating
considerable heterogeneity, 50% to 90% indicating substantial heterogeneity, and 30% to 60% indicating
moderate heterogeneity. If the I² value is equal to or greater than 75%, we will make an a priori decision not to
perform a meta-analysis; the Cochrane Review will then take a narrative form, and we will discuss all
comparisons according to the findings presented within the studies. Where possible, we will use meta-regression
techniques to investigate possible sources of heterogeneity.
Assessment of reporting biases
For future updates of the review, we will investigate outcome reporting bias using the Outcome
Reporting Bias in Trials (ORBIT) classification system, allocating studies a letter from A to I if selective
outcome reporting bias is suspected (Kirkham 2010). Reporting biases arise when the dissemination of
research findings is influenced by the nature and direction of results (Higgins 2011). Funnel plots can be used in
investigating reporting biases but are of limited power to detect small-study effects. We will not use funnel plots
for outcomes where there are 10 or fewer studies, or where all studies are of similar sizes.
Data synthesis
We did not perform meta-analysis in the review due to the heterogeneity in the reporting of results in two of the
included studies.
If we are able to perform meta-analysis in future updates of the review, we will synthesise data using the risk
ratio, odds ratio, mean difference, or standardised mean difference values depending on the measures used in
both the controlled and uncontrolled studies. We will carry out a sensitivity analysis to check for differences
between a random-effects model and fixed-effect model in influencing conclusions. If differences between the
models exist, we intend to report outcomes based on the random-effects model, which incorporates an
assumption that the different studies are estimating different, yet related, intervention effects.
For controlled studies, we intended to perform meta-analysis using the Mantel-Haenszel method for
dichotomous outcomes and the inverse variance method for continuous outcomes. For uncontrolled studies, we
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would have used the inverse variance method for continuous outcomes in meta-analysis.
We aimed to combine data for outcomes for the same intervention. We would not combine data from randomised
controlled and uncontrolled studies or from studies of prospective and retrospective designs.
We expected to perform the following comparisons of intervention group versus controls for:
number of SUDEP deaths;1.
number of non-SUDEP deaths;2.
number of hospital attendances;3.
change in depression score;4.
change in quality of life score.5.
We would have stratified each comparison by type of intervention to ensure appropriate combination of study
data.
Subgroup analysis and investigation of heterogeneity 
If we are able to perform meta-analysis for future updates of the review, we will stratify subgroup analyses by
type of intervention and duration of intervention. For investigation of heterogeneity, please see the Assessment
of heterogeneity section.
Sensitivity analysis
If we are able to perform meta-analysis for future updates of the review, in the event of identifying any
inconsistencies or peculiarities we will perform sensitivity analysis using only studies considered to be at low risk
of bias. We will compare the results from this second meta-analysis with the reports from the initial analysis,
which would include all studies.
Summary of findings and assessment of the certainty of the evidence
We have included the following outcomes in Summary of findings table 1: number of SUDEP deaths;
number of non-SUDEP deaths; depression and anxiety scores; quality of life; and number of hospital
attendances. We assessed the certainty of each outcome using the GRADE approach (Guyatt 2008).
Results 
Description of studies 
Results of the search
From searches conducted up to February 2019, we identified 1277 records from the databases and search
strategies outlined in Electronic searches. We found 10 further records by searching other resources
(handsearching). We removed 469 duplicate records and screened 818 records (title and abstract) for inclusion in
the review. We excluded 785 records based on the title and abstract and assessed 33 full-text articles for
inclusion in the review. We excluded 29 studies from the review (see Excluded studies below) and included
four studies (Langan 2005; Radhakrishnan 2018; Shankar 2016; van der Lende 2018).
See Figure 1 for a PRISMA study flow diagram.
Included studies
Of studies that met the inclusion criteria we identified one prospective cohort study (Radhakrishnan 2018
), and three case-control studies (Langan 2005; Shankar 2016; van der Lende 2018).
Participants (cohort study)
Radhakrishnan 2018 recruited consecutive people with epilepsy (PWE) aged over 15 years with a duration of
epilepsy of at least one month from a tertiary care teaching hospital in Northern India.
In total, 121 PWE were recruited to the intervention group (116 PWE retained to 6 months for analysis, 81 males
and 35 females, mean age 25.8 years) and 110 PWE were recruited to the control group (106 retained to 6
months for analysis, 76 males and 30 females, mean age 27.6 years). PWE in intervention and control groups
were balanced in terms of characteristics (age, duration of epilepsy, gender, education, type of epilepsy, family
history of epilepsy, seizure frequency, number of antiepileptic drugs, intelligence quotient, neuroimaging
findings and socioeconomic classification) and baseline scores of drug adherence, quality of life, anxiety and
depression outcome measures.
Caregivers of the PWE were also recruited; and for PWE with an intelligence quotient (IQ) of less than 80,
caregivers completed outcome measures on behalf of the PWE. No information is given, however, about how
many caregivers were recruited with PWE and characteristics of caregivers.
Participants (case-control studies)
Langan 2005 included 154 cases in which postmortem examination between 1989 to 1998 had been performed
and a diagnosis of SUDEP, as per the operational definition outlined above, had been made. Cases were identified
through coroner reports, the British Neurologic Surveillance Unit, and the UK support charity Epilepsy Bereaved.
Each case had four controls with epilepsy, matched for age and geographical area and identified through the
Medical Research Council (MRC) General Practice Research Framework. The cases included 97 men and 57 women
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with a mean age of 32 years. Demographic details for controls were not reported.
Shankar 2016 included 48 SUDEP cases aged between 2 and 82 years at death, identified from all 93 epilepsy
and epilepsy-associated deaths which occurred in the UK county of Cornwall between 2004 and 2012, as
recorded by the Cornwall Coroner. Controls were 220 outpatients attending epilepsy clinics within Cornwall. The
cases included 33 men and 15 women with a mean age of 42.5 years. The controls included 115 men and 105
women with a mean age of 42.7 years. No further demographic details were reported for either the cases or the
controls.
van der Lende 2018 included 60 SUDEP cases which occurred in individuals under the age of 60 (mean age 39.3
years, 42 males and 18 females) at two epilepsy residential care facilities in the Netherlands and the UK between
1987 and 2014. Four controls per case were matched on age (± 5 years) and residential unit. The controls were
132 males and 66 females, mean age 40 years. Characteristics of SUDEP cases and controls were mostly similar
(epilepsy aetiology, epilepsy duration, seizure types, number of antiepileptic drugs and use of benzodiazepines).
SUDEP cases had a higher frequency of convulsive seizures (P = 0.001), however, particularly nocturnal
convulsive seizures (P < 0.001), and a higher intelligence quotient compared with controls (P = 0.005).
Interventions (cohort study)
Radhakrishnan 2018 was initiated in January 2016 as single arm design (pre-test/post-test design) with all
participants receiving the intervention (SUDEP information and standard epilepsy care) for six months. A control
group was added to the trial design in September 2017 due to concerns over bias. The control group were
recruited according to the same eligibility criteria and received only standard epilepsy care for six months and
the SUDEP information was provided to the control group at the end of the study period. Outcomes measured
were within-group changes from baseline to six months' drug adherence, quality of life, anxiety and depression.
No cases of SUDEP during the study are reported.
Interventions (case-control studies)
In Langan 2005, supervision at night was one of several factors listed as assessment variables between groups.
This was defined as the presence in the bedroom of an individual of normal intelligence and at least 10 years old
or the use of special precautions. Special precautions involved regular checks throughout the night or the use of
a listening device.
In Shankar 2016, night surveillance was one of 17 factors listed as assessment variables between groups, but the
number of cases and controls receiving or not receiving these interventions was not reported.
In van der Lende 2018, nocturnal supervision was an assessment variable between groups. Grades of nocturnal
supervision were defined as follows.
Grade 1: no central acoustic or listening device and sleeping alone and physical checks more than 15 minutes
apart.
Grade 2: central acoustic or listening device, having a roommate, having a physical check at least every 15
minutes.
Grade 3: central acoustic or listening device and dormitory; central acoustic or listening device and additional
device (e.g. bed motion sensor/video monitoring); central acoustic or listening device and having a physical
check at least every 15 minutes.
Within the residential facilities, all individuals were physically checked by carers (one carer to every 14 residents)
at least once or twice a night and additional checks were performed on a need basis. Therefore for the purposes
of this review, we define Grade 1 as no additional intervention (i.e. 'no additional nocturnal supervision') and
Grades 2 and 3 combined as 'additional nocturnal supervision'.
All of these retrospective case-control studies also considered other factors that were not relevant to this review;
see Characteristics of included studies for details. Depression treatment (including SSRIs) and presence of
anxiolytic medication were also examined as risk factors in Shankar 2016; however 'anxiolytic medication' was
not clearly defined and we interpreted 'depression treatment' to really be defined as the association between
clinical depression and SUDEP (rather than the use of interventions for depression to prevent against SUDEP). We
did not therefore judge 'depression treatment' or 'anxiolytic medication' to be relevant interventions for this
review.
Excluded studies
We excluded 29 studies. Eight studies did not assess interventions to prevent SUDEP (Almeida 2010; Annegers
1998; Annegers 2000; Bateman 2010; Fisher 2010; NCT00986310; Nilsson 2001; Ryvlin 2011); eight
studies were review articles rather than clinical studies (Asadi-Pooya 2009; DeGiorgio 2019; Devinsky 2018; 
Purnell 2018; Ryvlin 2018b; Schachter 2006; Scorza 2011; Verma 2015); six studies assessed risk
factors for SUDEP but not interventions for preventing SUDEP (DeGiorgio 2008; Kang 2017; Schmuely 2016; 
Seymour 2012; Sveinsson 2018; Terra 2012); five studies measured sensitivity of devices to detect GTCS
but did not directly measure SUDEP (Beniczky 2013; Narechania 2013; NCT00101933; Seyal 2013; Van Poppel
2013); and two studies did not have a control group (NCT00736424; Ryvlin 2018a).
Risk of bias in included studies 
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We rated risk of bias across each domain and then made an overall risk of bias judgement for the included
studies (Langan 2005; Radhakrishnan 2018; Shankar 2016; van der Lende 2018). We rated all three of the
case-control studies as having an overall serious risk of bias (Langan 2005; Shankar 2016; van der Lende 2018);
and Radhakrishnan 2018, the prospective cohort study, as having an overall critical risk of bias (see Table 1 for
guidance of how we rated the overall risk of bias in the studies and see Table 2, Table 3, Table 4 and Table 5 for
responses to signalling questions).
Bias due to confounding
Cohort study
We judged Radhakrishnan 2018 to be at critical risk of bias due to confounding. The outcomes measured within
the study were subjective (drug adherence, quality of life, depression and anxiety) which could be influenced by a
range of factors, including confounding factors. However most analyses do not control or adjust for any
confounders. For the outcome drug adherence, regression analysis was performed to characterise 'predictors of
adherence' but only in the subgroup of participants who demonstrated improved drug adherence. We consider
that it is inappropriate to exclude participants without improved drug adherence from an analysis of predictors of
adherence.
Case-control studies
We judged Langan 2005 and van der Lende 2018 to be at moderate risk and Shankar 2016 to be at serious risk
of bias due to confounding. For all three studies, the objective of the study was to examine a range of factors
associated with SUDEP, therefore confounding is inevitable. However, van der Lende 2018 performed a
multivariable analysis adjusting for convulsive seizure frequency (an important confounder) and Langan 2005
performed multivariable analyses and assessed variables independently of seizure frequency, but did not report
on control of other potential confounders (types of seizures, history of depression) between groups. Shankar
2016 presented only univariable analyses as "low numbers and missing data" which prevented a multivariable
analysis, and we judged that the univariable analyses reported are likely to be confounded.
Bias in selection of participants into the study
Cohort study
We judged Radhakrishnan 2018 to be at low risk of bias in the selection of participants into the study. Although
the control group was added to the study design 18 months after the start of the study and therefore
characteristics and outcomes of participants within the intervention group who had completed the 6-month
study period would have been known, it is stated that recruitment into both groups was "consecutive" and that
the control group was recruited using the same inclusion criteria — selection should not, therefore, have been
influenced.
Case-control studies
We judged Langan 2005 to be at low risk and Shankar 2016 and van der Lende 2018 to be at moderate risk of
bias for selection of participants into the study. In Langan 2005 and Shankar 2016, the selection of SUDEP cases
was clearly described; and controls were randomly selected from the eligible population and matched for sex and
geographical location in Langan 2005. In Shankar 2016, however, controls were selected consecutively but it was
unclear why cases and controls were considered over separate, non-overlapping time periods and whether any
selection bias could have occurred. Also in van der Lende 2018, it was unclear how many individuals were
reviewed when establishing SUDEP cases and exactly how matched controls were selected from the residential
facilities and whether any selection bias could have occurred.
Bias in classification of interventions
Cohort study
We judged Radhakrishnan 2018 to be at moderate risk of bias in classification of the intervention. As the control
group was added to the study design 18 months after the start of the study and therefore characteristics and
outcomes of participants within the intervention group who had completed the 6-month study period would have
been known, it is unclear whether both groups (intervention and control) or only the control group were recruited
to following the addition of the control group (i.e. whether the intervention groups were defined by the time
point).
Case-control studies
We judged Langan 2005 and Shankar 2016 to be at moderate risk of bias in classification of the intervention as it
is possible that intervention status was recorded after outcome and provided by a relative (rather than the case)
for the SUDEP cases in both studies, which could be a source of bias. In van der Lende 2018, where 'grades' of
nocturnal supervision were considered as the intervention, it is likely that the 'grades of intervention' were
defined for this study rather than defined at the start of the intervention and it is also unclear whether the grades
could have changed over time during the time period of the study; for example if an individual had additional
measures of nocturnal supervision some nights and no additional measures other nights, which grade would the
individual be classified as? It is also possible that classification of the grade of intervention may have been
affected by knowledge of case or control status; for example, more detailed records regarding interventions
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received may have been recorded for residents who died compared to residents who did not. Therefore we
judged van der Lende 2018 to be at serious risk of bias in measurement of the intervention.
Bias due to deviations from intended interventions
Cohort study
We judged Radhakrishnan 2018 to be at critical risk of bias for deviations from intended interventions.
Participants for whom depression and anxiety was detected in the intervention group did not receive
'reinforcement' SUDEP information at subsequent clinics. As one of the aims of the study was to examine the
impact of providing SUDEP information on anxiety and depression, this deviation will have directly impacted upon
the outcome.
Case-control studies
We judged Langan 2005 to be at moderate risk and Shankar 2016 and van der Lende 2018 to be at serious risk
of bias for deviations from intended interventions. In all three studies, the intervention of interest to this review
was not intended to be the only 'intervention' in the study, adherence to the intervention was not reported,
switching may have occurred, and co-interventions may have been present. In Shankar 2016, furthermore, very
limited information about the interventions was available and the number of cases and controls receiving or not
receiving the interventions was not reported. In van der Lende 2018, it was also not clear whether the 'grades' of
intervention could have changed during the time period of the study (see 'Bias in classification of interventions'
above).
Bias due to missing data
Cohort study
We judged Radhakrishnan 2018 to be at low risk of bias due to missing data. Outcome data was available for 96%
of recruited participants in the intervention and control groups, and it appears that the few missing patients were
lost to follow-up or did not complete all of the outcome measures to be included in analysis at the end of the 6-
month study period.
Case-control studies
We judged van der Lende 2018 to be at moderate risk of bias due to missing data. Around 20% of included cases
and controls were excluded from analysis due to missing data and no reasons were given for the missing data.
As the amount of missing data is relatively small and balanced across cases and controls, it is unlikely
conclusions would have been changed by this missing data.
We judged Langan 2005 and Shankar 2016 to be at serious risk of bias due to missing data. In Langan 2005,
there was a large proportion of missing data for the outcome "nocturnal supervision", with around 40% missing
data for controls, and an imbalance of missing data between cases and controls. In Shankar 2016, "low numbers
and missing data" prevented a multivariable analysis; it is not, however, stated which data were missing and how
many participants were included in the analysis of each factor related to SUDEP.
Bias in measurement of outcomes
Cohort study
We judged Radhakrishnan 2018 to be at moderate risk of bias for measurement of the outcome. Outcomes of the
study were subjective and measured by questionnaires administered directly to participants. As participants
would have been aware of their intervention status when completing the questionnaires, their intervention status
may have influenced their responses.
Case-control studies
We judged Langan 2005 and Shankar 2016 to be at low risk of bias for measurement of the outcome, since the
objective outcome measurement (SUDEP or no SUDEP) was established before intervention status. We judged van
der Lende 2018 to be at moderate risk of bias as although the outcome measurement is 'Objectives', it was
unclear exactly how cases and controls were selected into the study and whether intervention status (i.e. the
'grades' of interventions) was classified before or after outcome status was established.
Bias in selection of the reported result
Cohort study
We judged Radhakrishnan 2018 to be at critical risk of bias due to selection of the reported result. Mostly within-
group analyses only are reported and no between-group analyses are reported for the secondary outcomes. As
noted in 'Bias due to deviations from intended interventions' above, inconsistent delivery of the intervention to
participants with anxiety and depression detected at baseline will have directly impacted on the results for these
outcomes. In addition a regression analysis was performed to examine characteristics which predict adherence
but only in the subgroup of participants with improved adherence. This is clearly not an appropriate analysis.
Case-control studies
We judged all three of the studies to be at moderate risk of bias due to selection of the reported result. In Langan
2005 and van der Lende 2018, results of only a single multivariable model were reported, and it is unclear if
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results would have been different for other multivariable models. Furthermore for van der Lende 2018, it was
unclear if results would have been different if 'grade of intervention' could have been classified differently. In
Shankar 2016, it was unclear how the factors analysed were selected and if other factors were considered or if
alternative analyses had been conducted.
Effects of interventions 
See Summary of findings table 1 for a summary of the findings of the review. We judged all evidence to be of very
low certainty due to the retrospective, observational design of the included studies and serious risk of bias,
mainly relating to confounding, missing data and lack of reported information regarding selection into the study,
control groups and classification of intervention status.
Primary outcome: number of deaths from SUDEP
Cohort study
The prospective cohort study did not measure the number of deaths from SUDEP as an outcome
and no deaths (all cause) were reported during the study (Radhakrishnan 2018). However, the 6-month duration
of this study was likely too short to measure the direct impact of the interventions on the number of deaths from
SUDEP.
Case-control studies
All three included case-control studies contributed data to this outcome. All studies examined the association of
a range of factors to SUDEP; factors (interventions) relevant to this review were nocturnal supervision and special
precautions in Langan 2005: and nocturnal supervision in Shankar 2016 and in van der Lende 2018.
In Langan 2005, all 154 SUDEP cases had data for the presence or absence of the intervention, but data for the
presence or absence of the intervention was reported for only 367 out of 616 (60%) of controls. In Shankar 2016,
it is not reported how many of the 48 SUDEP cases and 220 control participants had data for the presence or
absence of the intervention; unadjusted odds ratios are presented without details of the number of participants
contributing to each analysis. In van der Lende 2018, data for the presence or absence of the intervention was
reported for 48 out of 60 SUDEP cases (80%) and 163 out of 198 controls (82%). Furthermore, due to the setting
of van der Lende 2018 (epilepsy residential facilities), all participants had some level of nocturnal supervision and
for the purposes of this review we are comparing additional measures of nocturnal supervision to no additional
measures of nocturnal supervision.
Due to this heterogeneity in the setting of the studies and in the reporting of results, we have not combined the
results for nocturnal supervision. The association between SUDEP and each intervention in each study is
presented narratively below.
Langan 2005 presented results such that odds ratio (OR) less than 1 indicates that the intervention is protective
against SUDEP (i.e. fewer cases of SUDEP occurred when the intervention was present compared to when the
intervention was absent), while Shankar 2016 and van der Lende 2018 presented results such that OR greater
than 1 indicates that the intervention is protective against SUDEP.
For consistency of interpretation, for the results presented in this review we assume that OR less than 1 indicates
that the intervention is protective against SUDEP, and therefore we have inverted the direction of the results for
Shankar 2016 and van der Lende 2018 (but we have reported results by grade of nocturnal supervision using the
original direction as reported by van der Lende 2018).
Nocturnal supervision compared to no nocturnal supervision
Langan 2005 found a protective effect for the presence of nocturnal supervision (adjusted OR from multivariable
logistic regression 0.40, 95% confidence interval (CI) 0.20 to 0.80). This effect was independent of seizure
control (see Characteristics of included studies for details of variables adjusted for).
Based on the number of cases and controls reported with nocturnal supervision, we calculated unadjusted ORs.
We still found a protective effect in unadjusted analysis: OR 0.34, 95% CI 0.22 to 0.53; P < 0.0001; Analysis 1.1).
Shankar 2016 also reported a protective effect for the presence of nocturnal supervision: unadjusted OR 0.08,
95% CI 0.02 to 0.27; P < 0.0001; Analysis 1.2).
van der Lende 2018 found no significant effect of additional nocturnal supervision compared to no additional
nocturnal supervision on SUDEP (unadjusted OR 0.76, 95% CI 0.40 to 1.46; P = 0.41; Analysis 1.3).
van der Lende 2018 reported three grades of nocturnal supervision (see Included studies for definitions). Results
for SUDEP cases and controls by grade are reported in Table 6; the authors concluded no significant difference
between grade of nocturnal supervision (adjusted for number of nocturnal convulsive seizures).
Special precautions compared to no special precautions
Langan 2005 found a protective effect when a supervising person shared the same bedroom or when special
precautions, for example a listening device, were used (adjusted OR from multivariable logistic regression 0.10,
95% CI 0.00 to 0.30). This effect was independent of seizure control (see Characteristics of included studies for
details of variables adjusted for).
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Based on the number of cases and controls reported with special precautions, we calculated unadjusted ORs. We
still found a protective effect in unadjusted analysis: OR 0.41, 95% CI 0.20 to 0.82; P = 0.01; Analysis 1.4).
Secondary outcomes
Cohort study
The prospective cohort study reported change in mean depression and anxiety scores and change
in quality of life but did not report any deaths (unrelated to SUDEP) or number of hospital
attendances for seizures (Radhakrishnan 2018).
Change in depression and anxiety scores
Radhakrishnan 2018 measured the change in depression and change in anxiety from baseline to six months by
the Patient Health Questionnaire (PHQ-9) and by the Hamilton Anxiety Rating Scale (HAM-A) respectively. Within-
group changes only were reported; no between-group (i.e. the intervention group compared to the control
group) changes were available. Within-group changes are reported in Table 7. Radhakrishnan 2018 concluded
that there was no significant change in anxiety and depression scores after 6 months of follow-up in either
group.
Change in quality of life score
Radhakrishnan 2018 measured the change in quality of life from baseline to six months, measured by Quality of
Life in Epilepsy-31 (QOLIE-31) or the Quality of Life in Epilepsy for Adolescents (QOLIE-AD-48). Within-group
changes only were reported; no between-group (i.e. the intervention group compared to the control group)
changes were available. Within-group changes for the QOLIE-31 are reported in Table 7 (QOLIE-AD-48 results
were not reported). Radhakrishnan 2018 concluded that there was no significant change in quality of life scores
after six months of follow-up in either group.
Case-control studies
The three case-control studies did not report our secondary outcomes 'number of other deaths (unrelated
to SUDEP)', 'change in mean depression and anxiety scores (as defined within the study)', 'clinically
important change in quality of life', and 'number of hospital attendances for seizures' (Langan 2005; Shankar
2016; van der Lende 2018).
Discussion 
Summary of main results
We found one cohort study and three case-control studies of serious to critical risk of bias. The 6-
month cohort study reported no significant effect on drug compliance or on quality of life, anxiety
and depression levels when providing patients with SUDEP information compared to no
information. The study was of too short duration, with no deaths observed in either group, to
determine a protective effect (Radhakrishnan 2018). Two case-control studies reported a protective effect
for nocturnal supervision against SUDEP (Langan 2005; Shankar 2016). In one study the protective effect
was independent of seizure control, suggesting that nocturnal supervision is not just a surrogate marker
of seizure control (Langan 2005). This is important since additional results within the same study highlighted
increased risk for SUDEP with higher frequency of convulsive seizures, although not beyond 50 seizures in the
previous three months. The control of such seizures may be important in SUDEP prevention. The third case-
control study within two residential care settings where patients were already receiving physical checks more
than 15 minutes apart throughout the night did not report any protective effect for additional nocturnal
supervision (physical checks < 15 minutes apart, use of listening devices, dormitory setting and use of bed
sensors) (van der Lende 2018). However the same study did ascertain a difference between centres: the centre
with the lowest level of supervision had the highest incidence of SUDEP. The case-control studies did not report
on quality of life or depression and anxiety scores.
Overall completeness and applicability of evidence
This review highlights a significant deficiency within the evidence base for clinical studies of
preventative interventions against SUDEP. Many seizure-monitoring devices are available for purchase
for patients and carers, some of which have been shown to be effective at detecting GTCS (Beniczky 2013; 
Narechania 2013; NCT00101933; Seyal 2013; Van Poppel 2013). These devices may be marketed in such a way
as to suggest a preventative effect against SUDEP; this has not been borne out in the literature and requires much
more extensive clinical investigation. We made contact with several commercial companies manufacturing
seizure-monitoring devices (Cyberonics Inc, Emfit Ltd, Medtronic, Medpage Ltd, and Epi-Care) in order to obtain
any unpublished information relating to this review, but we were unsuccessful.
No information has been reported on the effectiveness of other interventions (safety pillows, SSRIs, inhibitors of
adenosine and opiate substances) in preventing SUDEP.
Certainty of the evidence
The evidence we have obtained is limited by being from four non-randomised studies, including three case-
control studies with an observational design and an overall serious to critical risk of bias across the studies.
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There is also the possible risk of publication bias given that none of the device companies contacted were willing
to share unpublished information on their devices.
We judged the certainty of the limited evidence available for this review to be very low (Summary of findings
table 1), mainly due to risks of bias relating to confounding, missing data and lack of reported information
regarding selection into the study, control groups and classification of intervention status, deviations from the
intended interventions and selection of the reported results, including inappropriate analysis methods.
Potential biases in the review process
There is a possible risk of publication bias in this review given that unpublished data were not made available by
device companies. It is also possible that despite the exhaustive searches carried out in this review, we have not
identified other sources of unpublished data. This can be more of an issue for reviews including observational
study designs such as this review.
We have carried out a quality assessment of the single included study appropriate to the observational study
design.
Agreements and disagreements with other studies or reviews
There are no other available reviews examining the preventative effect of interventions other than antiepileptic
drugs in the prevention of SUDEP in people with epilepsy.
Authors' conclusions 
Implications for practice 
This review provides very low certainty evidence of a preventative effect of nocturnal supervision against SUDEP.
As most SUDEP deaths are unwitnessed, timely supervision and administration of first aid post seizure recovery
are paramount. Clearly this, as well as the practical steps to be taken in providing such supervision, needs to be
discussed with carers of people who have frequent uncontrolled nocturnal seizures. Specific recommendations as
to the best form of nocturnal supervision in preventing SUDEP risk requires further research.
This review has highlighted an overall deficiency in the literature base on the effectiveness of a wide range
of interventions in the prevention of SUDEP in people with epilepsy. We did not include antiepileptic drugs
as an intervention in this review, although a systematic review of placebo-controlled trials of adjunctive
antiepileptic drugs ascertained lower rates of definite or probable SUDEP in the active treatment arm (OR
0.17, 95% CI 0.05 to 0.57; P = 0.0046). The same review concluded that treatment with adjunctive
medication may have reduced the incidence of definite or probable SUDEP by more than seven times
compared with placebo in people with previously uncontrolled seizures (Ryvlin 2011). This information supports
the consideration of further trials of antiepileptic drugs in patients who fail to achieve remission on trials of
monotherapy, provided patients are compliant.
Over the years several seizure-monitoring devices have been marketed for private purchase by patients and
carers. These devices have varying sensitivities in their capacity to detect seizures, and thus prompt early
intervention. Some companies may have marketed devices on the basis of SUDEP, given the risk with nocturnal
tonic-clonic seizures; however a preventative effect has not been borne out from our review of the literature
base.
We have identified one report of the effects of providing SUDEP information to patients with epilepsy. This
short-duration study did not provide any evidence of a protective effect against SUDEP or ascertain a
significant improvement in drug compliance or change in anxiety and depression levels. The American
Academy of Neurology practice guidelines, National Institute of Clinical Excellence guidelines and the
Scottish Intercollegiate Guidelines Network (SIGN) all advise discussion of tailored information about
SUDEP (Harden 2017; NICE 2012: SIGN 2015). There is also evidence that patients and families wish to
be informed of the risk of SUDEP (Tonberg 2015). There is, however, no consensus as to the form or content of
the information, particularly given the uncertain pathophysiology and the lack of evidence base around
preventative measures as encountered in this review.
We have not identified any reported evidence of a preventative effect for other interventions purported to reduce
the risk of SUDEP via preventing airway obstruction or cardiorespiratory arrest, or both.
Implications for research 
Despite the clinical importance of SUDEP in epilepsy and the greater risk with more frequent nocturnal
seizures, our understanding of the exact pathophysiology of the event is currently unknown. This makes
advancing research into preventative interventions against SUDEP more challenging. Any research
observing preventative effects against SUDEP would require observational designs recruiting large numbers
of patients with long durations of follow-up given the small number of cases per year of SUDEP. Whilst not
impossible, these studies often require significant funding resources. An interesting area to examine would
be the utility of SSRIs both as an antiepileptic and as a preventative intervention for SUDEP. Three small
observational studies have demonstrated an antiepileptic effect with SSRIs, although sample sizes were
small and the duration of treatment ranged between four and 14 months (Favale 1995; Favale 2003; Specchio
2004).
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In the digital world, a novel app (EpSMon; www.sudep.org/epilepsy-self-monitor) has been developed to monitor
seizures, medication, and overall well-being to provide a more personalised approach to managing risk of
SUDEP, which could fluctuate over the course of time. This will provide ample opportunity to collect prospective
annual data nationwide linking clinical factors, interventions, and antiepileptic drugs to overall SUDEP risk so that
better-quality and more uniform information can be gathered about how to prevent SUDEP.
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Methods Case-control study performed in the UK
 
Participants 154 SUDEP cases aged between 16 and 50 years at death, identified between
1989 to 1998 through coroner reports, the British Neurologic Surveillance
Unit, and the UK support charity Epilepsy Bereaved. Each case had 4 controls
with epilepsy (total of 616 controls), matched for age and geographical area
and identified through the Medical Research Council (MRC) General Practice
Research Framework.
The cases included 97 men and 57 women with a mean age of 32 years.
Demographic details for controls were not reported, but it was stated that
controls were age matched within 5 years of cases.
 
Interventions Supervision at night was 1 of several factors listed as assessment variables
between groups (see 'Outcomes' below for details of other factors not relevant
to this review). This was defined as the presence of an individual of normal
intelligence and at least 10 years old in the bedroom or the use of special
precautions. Special precautions involved regular checks throughout the night
or the use of a listening device.
 
Outcomes Association of case or control status with factors including supervision at
night and use of special precautions (other factors not relevant to this review:
duration of epilepsy, seizure type and control including changes in seizure
severity, treatment history and compliance, recent antiepileptic drug
withdrawal, concomitant use of psychotropic medication, family history of
sudden death, learning disability, electroencephalogram changes, history of
drug or alcohol abuse, presence of other medical conditions, level of
attendance at doctor or hospital appointments).
 
Notes Analyses were based on data available retrospectively, therefore not all cases
and controls contributed to each factor.
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Bias due to confounding Unclear risk Moderate risk of bias: The objective of the study means that
confounding is inevitable. The study assessed variables
independently of seizure frequency, but did not report on control
of other potential confounders (types of seizures, history of
depression) between groups.
 
Bias in selection of participants
into the study
Low risk Low risk of bias: Controls were randomly selected from the
eligible population and matched for age and geographical
location.
 
Bias in measurement of
interventions
Unclear risk Moderate risk of bias: For cases, it is possible that intervention
status was recorded after outcome and provided by a relative
(rather than the case), which could be a source of bias.
 
Bias due to departures from
intended interventions
Unclear risk Moderate risk of bias: The intervention of interest to this review
was not intended to be the only 'intervention' in the study.
Switching may therefore have occurred, and co-interventions may
have been present.
 
Bias due to missing data High risk Serious risk of bias: There was a large proportion of missing data
for the variable nocturnal supervision, with around 40% missing
data for controls, and an imbalance of missing data between
cases and controls
 
Bias in measurement of
outcomes
Low risk Low risk of bias: The objective outcome measurement was
established before intervention status.
 
Bias in selection of the reported
result
Unclear risk Moderate risk of bias: Results for 1 multivariable model reported,
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Methods Prospective cohort study with a pre-test/post-test design conducted at a
tertiary care teaching hospital in Northern India
 
Participants Consecutive people with epilepsy (PWE) aged over 15 years with a duration of
epilepsy of at least 1 month were recruited; 119 inpatients and 112
outpatients
Mean (standard deviation) age of PWE included in analysis: intervention group
= 25.80 (8.19) years; control group = 27.59 (8.43) years
Mean (standard deviation) duration of epilepsy included in analysis:
intervention group = 14.82 (7.91) years; control group = 16.78 (8.41) years
Caregivers of the PWE were also recruited but no information is given about
how many caregivers were recruited with PWE and characteristics of caregivers
 
Interventions Intervention group: SUDEP information plus standard epilepsy care for 6
months (n = 121 recruited, n = 116 available for post-test analysis)
Control group: standard epilepsy care only for 6 months (n = 110, n = 106
available for post-test analysis)




Change in antiepileptic drug adherence from baseline to 6 months,1.
measured by Modified Morisky Medication Adherence Scale (MMAS)
Secondary outcomes
Change in quality of life from baseline to 6 months, measured by Quality of1.
Life in Epilepsy-31 (QOLIE-31) or Quality of life in Epilepsy for Adolescents
(QOLIE-AD-48)
Change in anxiety from baseline to 6 months, measured by Hamilton2.
Anxiety Rating Scale (HAM-A)
Change in depression from baseline to 6 months, measured by Patient3.
Health Questionnaire (PHQ-9)
 
Notes The study was initiated in January 2016 as single arm design with all
participants receiving the intervention (SUDEP information and standard
epilepsy care) for 6 months. A control group was added to the trial design in
September 2017 due to concerns over bias. The control group were recruited
according to the same eligibility criteria and received only standard epilepsy
care for 6 months.
PWE in intervention and control groups were balanced in terms of
characteristics (age, duration of epilepsy, gender, education, type of epilepsy,
family history of epilepsy, seizure frequency, number of antiepileptic drugs,
intelligence quotient, neuroimaging findings and socioeconomic classification)
and baseline scores of MMAS, QOLIE-31 or QOLIE-AD-48, HAM-A and PHQ-9.
Within-group (pre-test/post-test in the intervention and control groups) only
are made, no statistical comparisons of the intervention and control groups
post-test are made.
 
Risk of bias table
Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP)
19 / 54
Bias Authors'judgement Support for judgement
Bias due to confounding High risk Critical risk of bias: subjective outcomes are measured in this
study which could be influenced by factors, including confounding
factors. However most analyses do not control or adjust for any
confounders. A regression analysis is performed to examine which
characteristics 'predictors of adherence' in the subgroup of
participants with improved drug adherence. It is not appropriate to
exclude those without improved drug adherence from an analysis
of predictors of adherence.
 
Bias in selection of participants
into the study
Low risk Low risk of bias: the control group was added to the study design
18 months after the start of the study, therefore characteristics
and outcomes of participants within the intervention group who
had completed the 6-month study period would have been known
and a period effect could in theory be present. However, it is
stated that recruitment into both groups was "consecutive" and
that the control group was recruited using the same inclusion
criteria, therefore selection should not have been influenced.
 




Moderate risk of bias: the control group was added to the study
design 18 months after the start of the study, therefore
characteristics and outcomes of participants within the
intervention group who had completed the 6-month study period
would have been known. It is unclear whether both groups
(intervention and control) or only the control group were recruited
to following the addition of the control group (i.e. whether the
intervention groups were defined by the time point).
 
Bias due to departures from
intended interventions
High risk Critical risk of bias: participants for whom depression and anxiety
was detected in the intervention group did not receive
'reinforcement' SUDEP information at subsequent clinics. As 1 of
the aims of the study was examine the impact of providing the
SUDEP information on anxiety and depression, this deviation will
have directly impacted upon the outcome.
 
Bias due to missing data Low risk Low risk of bias: outcome data available for 96% of recruited
participants in the intervention and control groups and it appears
that the few missing patients were lost to follow-up or did not
complete all of the outcome measures to be included in analysis at
the end of the 6-month study period.
 




Moderate risk of bias: outcomes of the study were subjective and
measured by questionnaires administered directly to participants.
As participants would have been aware of their intervention status
when completing the questionnaires, their intervention status may
have influenced their responses.
 
Bias in selection of the reported
result
High risk Critical risk of bias: mostly within-group analyses only are
reported and no between-group analyses are reported for the
secondary outcomes. A regression analysis is performed to
examine which characteristics 'predictors of adherence' in the
subgroup of participants with improved adherence only which is
not an appropriate analysis.
 
Shankar 2016
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Methods Case-control study performed in the UK
 
Participants 48 SUDEP cases aged between 2 and 82 years at death, identified from all 93
epilepsy and epilepsy-associated deaths which occurred in Cornwall (UK)
between 2004 and 2012, as recorded by the Cornwall Coroner. Controls were
220 outpatients attending epilepsy clinics within Cornwall.
The cases included 33 men and 15 women with a mean age of 42.5 years
The controls included 115 men and 105 women with a mean age of 42.7 years
 
Interventions Night surveillance was 1 of 17 factors listed as assessment variables between
groups (see 'Outcomes' below for details of other factors not relevant to this
review)
 
Outcomes Association of case or control status with factors including Night surveillance
(Other factors not relevant to this review: sleeping in a prone position, unclear
treatment history, generalised tonic-clonic epilepsy, increasing seizure
frequency, compliance issues, alcohol problems, subtherapeutic AED levels,
epilepsy duration over 15 years, early onset epilepsy, frequent AED changes,
presence of anxiolytic medication, depression treatment, intellectual disability,
male gender, carbamazepine treatment, increasing seizure frequency).
 
Notes Very little information provided (other than age and gender) of the cases and
controls, and justification of the factors examined.
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Bias due to confounding High risk Serious risk of bias: the objective of the study means that
confounding is inevitable and no multivariable analysis was
conducted. Therefore the univariable analyses reported are likely
to be confounded.
 
Bias in selection of participants
into the study
Unclear risk Moderate risk of bias: selection of cases clearly described.
Controls selected consecutively but unclear why cases and
controls were considered over separate, non-overlapping time
periods and whether any selection bias could have occurred.
 
Bias in measurement of
interventions
Unclear risk Moderate risk of bias: for cases, it is possible that intervention
status was recorded after outcome and provided by a relative
(rather than the case), which could be a source of bias.
 
Bias due to departures from
intended interventions
High risk Serious risk of bias: Intervention of interest to us was not
intended to be the only 'intervention' in the study. No information
is given regarding the interventions, adherence to the
intervention, and co-interventions may have been present.
 
Bias due to missing data High risk Serious risk of bias: "Low numbers and missing data" prevented a
multivariable analysis; however it is not stated which data were
missing and how many participants were included in the analysis
of each factor related to SUDEP.
 
Bias in measurement of
outcomes
Low risk Low risk of bias: the objective outcome measurement was
established before intervention status
 
Bias in selection of the reported
result
Unclear risk Moderate risk of bias: unclear how the factors analysed were
selected and if other factors were considered or if alternative
analyses had been conducted
 
van der Lende 2018
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Methods Nested case-control study in two epilepsy residential care facilities in the
Netherlands and the UK
 
Participants 60 SUDEP cases under the age of 60 years, which occurred at two epilepsy
residential care facilities in the Netherlands and the UK (Stichting Epilepsie
Instellingen Nederland (SEIN) and Chalfont Centre for Epilepsy (CCE)) between
1987 and 2014.
4 controls per case were matched on age (±5 years) and residential unit, with
the date of death of the SUDEP cases uses as an index date for matching
controls.
The cases were 42 males and 18 females, mean age 39.3 years.
The controls were 132 males and 66 females, mean age 40 years.
 
Interventions Nocturnal supervision was 1 of 5 listed as assessment variables between
groups (see 'Outcomes' below for details of other factors not relevant to this
review).
 
Outcomes Association of case or control status with factors including nocturnal
supervision.
(Other factors not relevant to this review: having convulsive seizures,
frequency of convulsive seizures, having nocturnal convulsive seizures,
frequency of nocturnal convulsive seizures).
 
Notes Characteristics of SUDEP cases and controls were mostly similar (epilepsy
etiology, epilepsy duration, seizure types, number of antiepileptic drugs and
use of benzodiazepines). However SUDEP cases had a higher frequency of
convulsive seizures (P = 0.001), particularly nocturnal convulsive seizures (P <
0.001), and a higher intelligence quotient compared with controls (P = 0.005).
 
Risk of bias table
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Bias Authors'judgement Support for judgement
Bias due to confounding Unclear risk Moderate risk of bias: the objective of the study means that
confounding is inevitable; however from the information available,
it seems that confounders were measured fairly accurately and an
appropriate adjusted analysis adjusting for convulsive seizure
frequency (an important confounder) was performed.
 
Bias in selection of participants
into the study
Unclear risk Moderate risk of bias: unclear how many participants were
reviewed when establishing SUDEP cases and exactly how
matched controls were selected from the residential facilities.
Unclear if any selection bias could have been present.
 
Bias in measurement of
interventions
High risk Serious risk of bias: likely that the 'grades of intervention' were
defined for this study rather than at the start of the intervention,
unclear whether the grades could have changed over time and it is
possible that classification of the grade of intervention may have
been affected by knowledge of case or control status.
 
Bias due to departures from
intended interventions
High risk Serious risk of bias: intervention of interest to us was not
necessarily intended to be the only 'intervention' in the study. No
information is given regarding adherence to the intervention, the
consistency of the intervention and whether the 'grade' of the
intervention could have changed over time and co-interventions
may have been present.
 
Bias due to missing data Unclear risk Moderate risk of bias: around 20% of included cases and controls
were excluded from analysis due to missing data but as the
amount of missing data is relatively small and balanced across
cases and controls, it is unlikely conclusions would have been
changed by this missing data.
 
Bias in measurement of
outcomes
Unclear risk Moderate risk of bias: objective outcome measurement, but
unclear exactly how cases and controls were selected into the
study and whether intervention status was determined after
outcome status.
 
Bias in selection of the reported
result
Unclear risk Moderate risk of bias: results for 1 multivariable model reported,
unclear if results would have been different for other multivariable




SUDEP: Sudden Unexpected Death in Epilepsy
Due to different options for the 'Risk of bias' judgement in the non-randomised studies tool (Sterne 2016), we
have assigned 'critical serious risk of bias' and 'serious risk of bias' as 'high risk of bias' and 'moderate risk of
bias' as 'unclear risk of bias' in the table above. See the 'Support for judgement' column for more information and
Table 2, Table 3, Table 4 and Table 5 for full quality assessments with signalling questions.
Characteristics of excluded studies 
Almeida 2010
Reason for exclusion Did not assess interventions to prevent SUDEP
 
Annegers 1998
Reason for exclusion Did not assess interventions to prevent SUDEP
 
Annegers 2000
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Reason for exclusion Did not assess interventions to prevent SUDEP
 
Asadi-Pooya 2009
Reason for exclusion Review article, not a clinical study
 
Bateman 2010
Reason for exclusion Did not assess interventions to prevent SUDEP
 
Beniczky 2013
Reason for exclusion Measured sensitivity of devices to detect generalised tonic-clonic seizures but
did not directly measure SUDEP
 
DeGiorgio 2008
Reason for exclusion Assessed risk factors for SUDEP but not interventions for preventing SUDEP
 
DeGiorgio 2019
Reason for exclusion Review article, not a clinical study
 
Devinsky 2018
Reason for exclusion Review article, not a clinical study
 
Fisher 2010
Reason for exclusion Did not assess interventions to prevent SUDEP
 
Kang 2017
Reason for exclusion Assessed risk factors for SUDEP but not interventions for preventing SUDEP
 
Narechania 2013
Reason for exclusion Measured sensitivity of devices to detect generalised tonic-clonic seizures but
did not directly measure SUDEP
 
NCT00101933
Reason for exclusion Measured sensitivity of devices to detect generalised tonic-clonic seizures but
did not directly measure SUDEP
 
NCT00736424
Reason for exclusion All participants had neuro-stimulation, no control group
 
NCT00986310
Reason for exclusion Did not assess interventions to prevent SUDEP
 
Nilsson 2001
Reason for exclusion Did not assess interventions to prevent SUDEP
 
Purnell 2018
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Reason for exclusion Review article, not a clinical study
 
Ryvlin 2011
Reason for exclusion Did not assess interventions to prevent SUDEP
 
Ryvlin 2018a
Reason for exclusion All participants had vagus nerve stimulation, no control group
 
Ryvlin 2018b
Reason for exclusion Review article, not a clinical study
 
Schachter 2006
Reason for exclusion Review article, not a clinical study
 
Schmuely 2016
Reason for exclusion Assessed risk factors for SUDEP but not interventions for preventing SUDEP
 
Scorza 2011
Reason for exclusion Review article, not a clinical study
 
Seyal 2013
Reason for exclusion Measured sensitivity of devices to detect generalised tonic-clonic seizures but
did not directly measure SUDEP
 
Seymour 2012
Reason for exclusion Assessed risk factors for SUDEP but not interventions for preventing SUDEP
 
Sveinsson 2018
Reason for exclusion Assessed risk factors for SUDEP but not interventions for preventing SUDEP
 
Terra 2012
Reason for exclusion Assessed risk factors for SUDEP but not interventions for preventing SUDEP
 
Van Poppel 2013
Reason for exclusion Measured sensitivity of devices to detect generalised tonic-clonic seizures but
did not directly measure SUDEP
 
Verma 2015
Reason for exclusion Review article, not a clinical study
 
Footnotes
SUDEP: Sudden Unexpected Death in Epilepsy
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
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Footnotes
Summary of findings tables
1 Interventions for compared with no intervention for preventing Sudden Unexpected Death in
Epilepsy (SUDEP)
Interventions for compared with no intervention for preventing Sudden Unexpected Death in Epilepsy (SUDEP)
Patient or population: cases of SUDEP and matched controls (number of deaths due to SUDEP) and consecutive
people with epilepsy from a tertiary care teaching hospital in Northern India (change in mean depression and
anxiety scores and change in quality of life)
Settings: outpatients and patients within an epilepsy residential facility (number of deaths due to SUDEP),
inpatients and outpatients from a tertiary care teaching hospital in Northern India (change in mean depression
and anxiety scores and change in quality of life).
Intervention: interventions to prevent SUDEP (nocturnal supervision and special precautions for number of
deaths due to SUDEP and SUDEP information for change in mean depression and anxiety scores and change in
quality of life)
Comparison: no intervention (including usual care or standard epilepsy care for all outcomes)
Outcomes

























A protective effect for the presence
of nocturnal supervision against
SUDEP was found in 2 studies,
including from an analysis adjusted
for other factors (adjusted OR 0.40,













1 study: 109 deaths out of
278 in the no intervention
group and 34 deaths out of
190 deaths in the
intervention group.
The other study did not
report how many of the
cases and controls received
an intervention or not, only













No significant effect of additional
nocturnal supervision compared to
















There was also no
significant difference














A protective effect for the presence
of nocturnal supervision against
SUDEP was found including from an
analysis adjusted for other factors
















109 deaths out of 278 in
the no intervention group
and 11 deaths out of 53

















There was no significant change
from baseline in anxiety and
depression scores after 6 months of









by the Patient Health
Questionnaire (PHQ-9) and
















There was no significant change
from baseline in quality of life scores
after 6 months of follow-up in either







Quality of life was
measured by the Quality of
Life in Epilepsy-31
(QOLIE-31) and by the
Quality of life in Epilepsy
for Adolescents (QOLIE-
AD-48); results were not

















*The basis for the assumed risk is the event rate in the control group. The corresponding risk (and its 95% CI) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NA: not applicable; OR: odds ratio; SUDEP: Sudden Unexpected Death in Epilepsy
GRADE Working Group grades of evidence
High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of
effect and may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of
effect and is likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.
Footnotes
a. Assumed and corresponding risks not calculated due to study design (case-control)
b. Quality of the evidence automatically started at 'low' due to the retrospective, observational design of the
included studies. Downgraded once to 'very low' due to serious risk of bias, mainly relating to confounding,
missing data and lack of reported information regarding selection into the study, control groups and
classification of intervention status.
c. Unadjusted odds ratio. OR < 1 indicates that the intervention is protective against SUDEP
d. Certainty of the evidence automatically started at 'low' due to the retrospective, observational design of the
included studies. Downgraded to 'very low' due to critical risk of bias relating to confounding, deviations from
the intended interventions and selection of the reported results, including inappropriate analysis methods.
Additional tables 
1 Guidance for making a single 'Risk of bias' judgement for an outcome based on 'Risk of bias'
judgements for the 7 domains of the ROBINS-I
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'Risk of bias' judgement for the outcome Criteria (based on 7 'Risk of bias' domains)
Low risk of bias (the study is comparable to a
well-performed randomised trial)
The study is judged to be at low risk of bias
for all domains
Moderate risk of bias (the study appears to
provide sound evidence for a non-randomised
study but cannot be considered comparable to
a well-performed randomised trial)
The study is judged to be at low or moderate
risk of bias for all domains
Serious risk of bias (the study has some
important problems)
The study is judged to be at serious risk of
bias in at least 1 domain, but not at critical
risk of bias in any domain
Critical risk of bias (the study is too
problematic to provide any useful evidence on
the effects of intervention)
The study is judged to be at critical risk of
bias in at least 1 domain
No information on which to base a judgement
about risk of bias
There is no clear indication that the study is at
serious or critical risk of bias, and there is a lack
of information in 1 or more key domains of
bias (a judgement is required for this)
Footnotes





Bias due to confounding
1.1 Is there potential for confounding
of the effect of intervention in this
study?
Y Aim of the study was to explore variables that may influence
the factors associated with SUDEP. The 'intervention' of
interest to us is 1 of those variables, so confounding is
inevitable
1.2. If Y or PY to 1.1 Was the analysis
based on splitting participants’ follow
up time according to intervention
received?
NA Case-control study, cases and controls were retrospectivelyexamined over the same period of time
1.4. Did the authors use an
appropriate analysis method that
adjusted for all the critically important
confounding domains?
PY Multivariable logistic regression, but variables that were not
significant in the model are not reported in the results
1.5. If Y or PY to 1.4: Were
confounding domains that were
adjusted for measured validly and
reliably by the variables available in
this study?
PY Variables taken from a Medical Research Council (MRC)
database/coroners' records/interviews with bereaved
families. Probably fairly accurate
1.6. Did the authors control for any
post- intervention variables that could
have been affected by the
intervention?
PN Intervention is given over a period of time, and variables are
also measured over a period of time with probable overlap
1.7. Did the authors use an
appropriate analysis method that
controlled for all the important
confounding domains and for time-
varying confounding?
NA
Case-control study, cases and controls were examined over
the same period of time
'Risk of bias' judgement Moderate The objective of the study means that confounding is
inevitable; however from the limited information available, it
seems that an appropriate adjusted analysis was performed
 
Bias in selection of participants into the study






2.1. Was selection of participants into
the study (or into the analysis) based
on participant characteristics
observed after the start of
intervention?
N
Case-control study, therefore selection was based on
outcome (SUDEP or no SUDEP), not based on any
participants characteristics and not related to the
intervention
2.4 Do start of follow-up and start of
intervention coincide for most
participants?
PN
Cases and controls are examined over a fixed period and it
is not stated when any interventions were started for the
cases and controls, unlikely that interventions were started
at the beginning of the time period of interest for most
participants
2.5 If N or PN to 2.4 Were adjustment
techniques used that are likely to
correct for the presence of selection
biases?
PN Controls were randomly sampled from a national database
so unlikely that any selection bias was presented, therefore
adjustment techniques probably not required
'Risk of bias' judgement Low Random sample of controls used and no evidence of any
selection bias
 
Bias in classification of interventions
3.1 Were intervention groups clearly
defined?
Y Clear whether a participant had any of the listed
supervision, but data for the controls missing
3.2 Was the information used to
define intervention groups recorded at
the start of the intervention?
PY For controls, likely recorded at the time of intervention
(continuous intervention over a period of time). For cases,
this information may have been recorded following the
outcome and information provided by a relative rather than
the case (deceased)
3.3 Could classification of intervention
status have been affected by
knowledge of the outcome or risk of
the outcome?
PN For controls, likely recorded at the time of intervention
(continuous intervention over a period of time). For cases,
this information may have been recorded following the
outcome and information provided by a relative rather than
the case (deceased)
'Risk of bias' judgement Moderate For cases, it is possible that intervention status was
recorded after outcome, which could be a source of bias
 
Bias due to deviations from intended interventions (aim for this study is to assess the effect of starting and
adhering to intervention)
4.3. Were important co-interventions
balanced across intervention groups?
N Number of AEDs and current use of carbamazepine not
balanced across cases and controls
4.4. Was the intervention
implemented successfully for most
participants?
NI
No information given but possible that intervention could
be disrupted (e.g. person supervised leaves the room) or
devices fail
4.5. Did study participants adhere to
the assigned intervention regimen? NI
No information given regarding adherence to the
interventions
4.6. If N or PN to 4.3, 4.4 or 4.5 Was
an appropriate analysis used to
estimate the effect of starting and
adhering to the intervention?
N
Adherence to the intervention is not mentioned or taken
account of in analysis
'Risk of bias' judgement Moderate Intervention of interest to us was not intended to be the
only 'intervention' in the study. No information is given
regarding adherence to the intervention, and co-
interventions may have been present
 






Bias due to missing data
5.1 Were outcome data available for
all, or nearly all, participants?
Y Participants selected based on outcome status (case-control
study)
5.2 Were participants excluded due to
missing data on intervention status?
Y A lot of missing data for the controls for intervention status
5.3 Were participants excluded due to
missing data on other variables
needed for the analysis?
Y Data also missing for controls for other variables
5.4 If PN/N to 5.1, or Y/PY to 5.2 or
5.3: Are the proportion of participants
and reasons for missing data similar
across cases and controls?
N A lot of missing data for controls, mostly complete for cases
5.5 If PN/N to 5.1, or Y/PY to 5.2 or
5.3: Is there evidence that results
were robust to the presence of
missing data?
N Participants and variables with missing data excluded from
analysis
'Risk of bias' judgement Serious A large proportion of missing data for outcome status and
an imbalance of missing data across cases and controls
 
Bias in measurement of outcomes
6.1 Could the outcome measure have
been influenced by knowledge of the
intervention received?
N Cases were those who had experienced SUDEP, controls had
not experienced SUDEP
6.2 Were outcome assessors aware of
the intervention received by study
participants?
N By design, cases and controls established first and then
variable information including intervention status extracted
afterwards




By design, cases and controls established first and then
variable information including intervention status extracted
afterwards
6.4 Were any systematic errors in
measurement of the outcome related
to intervention received?
N
Cases were those who had experienced SUDEP, controls had
not experienced SUDEP, therefore very unlikely that any
errors related to measurement of the outcome occurred
'Risk of bias' judgement Low Objective outcome measurement established before
intervention status
 
Bias in selection of the reported result
Is the reported effect estimate likely to be selected, on the basis of the results, from...
7.1 ...multiple outcome measurements
within the outcome domain?
N A single and clearly defined outcome, SUDEP or no SUDEP.
7.2 ...multiple analyses of the
intervention-outcome relationship?
PN Multivariable analysis performed, unclear exactly how many
variables were included in the model and whether results
would have been different for the intervention-outcome
relationship if other non-significant variables had been
retained in the model
7.3 ...different subgroups? N No subgroups reported
'Risk of bias' judgement Moderate Results for 1 multivariable model reported, unclear if results
would have been different for other multivariable models
Footnotes
Abbreviations: Y: yes; PY: probably yes; PN: probably no; N: no; NI: no information
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AEDs: antiepileptic drugs
SUDEP: Sudden Unexpected Death in Epilepsy





Bias due to confounding
1.1 Is there potential for confounding
of the effect of intervention in this
study?
Y Aim of the study was to explore variables that may influence
the factors associated with SUDEP. The 'intervention' of
interest to us is 1 of those variables, so confounding is
inevitable
1.2. If Y or PY to 1.1 Was the analysis
based on splitting participants’
follow up time according to
intervention received?
PN
Case-control study, cases and controls were retrospectively
examined over completely different periods of time. The
rationale for this is unclear but is unlikely to be due to any of
the interventions of interest
1.4. Did the authors use an
appropriate analysis method that
adjusted for all the critically
important confounding domains?
N Univariable analysis only used (odds ratios calculated for
having a specific factor in those who died from SUDEP
compared to controls.) The authors stated that "low numbers
and missing data" prevented a multivariable analysis.
1.6. Did the authors control for any
post- intervention variables that
could have been affected by the
intervention?
N Univariable analysis only used (odds ratios calculated for
having a specific factor in those who died from SUDEP
compared to controls.) The authors stated that "low numbers
and missing data" prevented a multivariable analysis. No
variables controlled for (pre- or post-intervention)
1.7. Did the authors use an
appropriate analysis method that
controlled for all the important
confounding domains and for time-
varying confounding?
N Case-control study, no variables controlled for (pre- or post-intervention)
'Risk of bias' judgement Serious The objective of the study means that confounding is
inevitable and no multivariable analysis was conducted.
Therefore the univariable analyses reported are likely to be
confounded
 
Bias in selection of participants into the study
2.1. Was selection of participants into
the study (or into the analysis) based
on participant characteristics
observed after the start of
intervention?
PN
Case-control study, therefore selection was based on
outcome (SUDEP or no SUDEP). Selection of cases clearly
described
Not completely clear how the controls were selected (e.g.
how the time period that consecutive controls were chosen
was selected), but it does not appear to be related to
participants characteristics or any interventions.
2.4 Do start of follow-up and start of
intervention coincide for most
participants?
PN
Cases and controls are examined over a fixed time periods
and it is not stated when any interventions were started for
the cases and controls, unlikely that interventions were
started at the beginning of the time period of interest for
most participants
2.5 If N or PN to 2.4 Were adjustment
techniques used that are likely to
correct for the presence of selection
biases?
PN Not completely clear how the controls were selected and why
cases and controls were considered over separate, non-
overlapping time periods. No apparent adjustments made for
any selection biases.
'Risk of bias' judgement Moderate Selection of cases clearly described. Controls selected
consecutively but unclear why cases and controls were
considered over separate, non-overlapping time periods and
whether any selection bias could have occurred
 






Bias in classification of interventions
3.1 Were intervention groups clearly
defined?
PY Presumably presence or absence of the intervention or
factor, but unclear how the intervention and factor groups
were measured.
3.2 Was the information used to
define intervention groups recorded
at the start of the intervention?
PY For controls, likely recorded at the time of intervention
(continuous intervention over a period of time). For cases,
this information may have been recorded following the
outcome and information provided by a relative rather than
the case (deceased)
3.3 Could classification of
intervention status have been
affected by knowledge of the
outcome or risk of the outcome?
PY For controls, likely recorded at the time of intervention
(continuous intervention over a period of time). For cases,
this information may have been recorded following the
outcome and information provided by a relative rather than
the case (deceased)
'Risk of bias' judgement Moderate For cases, it is possible that intervention status was recorded
after outcome and provided by a relative (rather than the
case), which could be a source of bias
 
Bias due to deviations from intended interventions (aim for this study is to assess the effect of starting and
adhering to intervention)
4.3. Were important co-interventions
balanced across intervention groups?
NI No information provided regarding the number of cases and
controls receiving the interventions, only odds ratios for
having a specific factor in those who died from SUDEP
compared to controls presented
4.4. Was the intervention
implemented successfully for most
participants?
NI
No information provided regarding the number of cases and
controls receiving the interventions, only odds ratios for
having a specific factor in those who died from SUDEP
compared to controls presented
4.5. Did study participants adhere to
the assigned intervention regimen? NI
No information provided regarding the number of cases and
controls receiving the interventions, only odds ratios for
having a specific factor in those who died from SUDEP
compared to controls presented
4.6. If N or PN to 4.3, 4.4 or 4.5 Was
an appropriate analysis used to
estimate the effect of starting and
adhering to the intervention?
N Adherence to the intervention is not mentioned or takenaccount of in analysis
'Risk of bias' judgement Serious Intervention of interest to us was not intended to be the only
'intervention' in the study. No information is given regarding
the interventions, adherence to the intervention, and co-
interventions may have been present.
 
Bias due to missing data
5.1 Were outcome data available for
all, or nearly all, participants?
Y Participants selected based on outcome status (case-control
study)
5.2 Were participants excluded due
to missing data on intervention
status?
NI it does not appear that any participants were excluded from
the study completely due to missing data regarding
interventions, but numbers of participants included in the
analysis of each factor related to SUDEP is not provided so
unclear how much data was missing on intervention status






5.3 Were participants excluded due
to missing data on other variables
needed for the analysis?
NI "Low numbers and missing data" prevented a multivariable
analysis, however it is not stated which data was missing and
how many participants were included in the analysis of each
factor related to SUDEP
5.4 If PN/N to 5.1, or Y/PY to 5.2 or
5.3: Are the proportion of
participants and reasons for missing
data similar across interventions?
NI "Low numbers and missing data" prevented a multivariable
analysis, however it is not stated which data was missing and
how many participants were included in the analysis of each
factor related to SUDEP
5.5 If PN/N to 5.1, or Y/PY to 5.2 or
5.3: Is there evidence that results
were robust to the presence of
missing data?
N No examination of whether results are robust to missing data
'Risk of bias' judgement Serious "Low numbers and missing data" prevented a multivariable
analysis, however it is not stated which data was missing and
how many participants were included in the analysis of each
factor related to SUDEP
 
Bias in measurement of outcomes
6.1 Could the outcome measure have
been influenced by knowledge of the
intervention received?
N Cases were those who had experienced SUDEP, controls had
not experienced SUDEP
6.2 Were outcome assessors aware of
the intervention received by study
participants?
N By design, cases and controls established first and then
variable information including intervention status extracted
afterwards




By design, cases and controls established first and then
variable information including intervention status extracted
afterwards
6.4 Were any systematic errors in
measurement of the outcome related
to intervention received?
N
Cases were those who had experienced SUDEP, controls had
not experienced SUDEP, therefore very unlikely that any
errors related to measurement of the outcome occurred
'Risk of bias' judgement Low Objective outcome measurement established before
intervention status
 
Bias in selection of the reported result
Is the reported effect estimate likely to be selected, on the basis of the results, from...
7.1 ...multiple outcome
measurements within the outcome
domain?
N A single and clearly defined outcome, SUDEP or no SUDEP.
7.2 ...multiple analyses of the
intervention-outcome relationship?
NI Unclear how the factors analysed were selected and if other
factors were considered or if alternative analyses had been
conducted
7.3 ...different subgroups? N No subgroups reported
'Risk of bias' judgement Moderate Unclear how the factors analysed were selected and if other
factors were considered or if alternative analyses had been
conducted
Footnotes
Abbreviations: Y: yes; PY: probably yes; PN: probably no; N: no; NI: no information
AEDs: antiepileptic drugs
SUDEP: Sudden Unexpected Death in Epilepsy
4 Responses to ROBINS-I signalling questions and 'Risk of bias' judgements for Radhakrishnan 2018







Bias due to confounding
 
1.1 Is there potential for
confounding of the effect of
intervention in this study?
Y Intervention and control groups appear balanced for participant
characteristics and baseline outcome measures. However, outcomes
measured are drug adherence, quality of life, depression and anxiety
which are all subjective outcomes which could be influenced by a
range of factors, including confounding factors.
1.2. If Y or PY to 1.1: Was the




PN Participants were followed up for the same amount of time in both
groups (6 months) and it does not appear that interventions could be
switched during this time.
1.4. Did the authors use an
appropriate analysis method
that controlled for all the
important confounding
domains?
N Most analyses do not control or adjust for any confounders. A single
regression analysis is performed to examine which characteristics
'predictors of adherence' in the subgroup of participants with
improved adherence only which is not an appropriate analysis
1.6. Did the authors control
for any post- intervention
variables that could have
been affected by the
intervention?
N No post-intervention variables controlled for in any of the analyses
1.7. Did the authors use an
appropriate analysis method
that controlled for all the
important confounding
domains and for time-varying
confounding?
N Most analyses do not control or adjust for any confounders. A
regression analysis is performed to examine which characteristics
'predictors of adherence' in the subgroup of participants with
improved drug adherence. It is not appropriate to exclude those
without improved drug adherence from an analysis of predictors of
adherence.
'Risk of bias' judgement Critical Subjective outcomes are measured in this study which could be
influenced by a range of factors, including confounding factors.
However most analyses do not control or adjust for any confounders.
A univariate regression analysis is performed to examine which
characteristics 'predictors of adherence' in the subgroup of
participants with improved drug adherence. It is not appropriate to
exclude those without improved drug adherence from an analysis of
predictors of adherence.
 
Bias in selection of participants into the study
2.1. Was selection of
participants into the study (or
into the analysis) based on
participant characteristics
observed after the start of
intervention?
PN The control group was added to the study design 18 months after the
start of the study, therefore characteristics and outcomes of
participants within the intervention group who had completed the 6-
month study period would have been known and a period effect could
in theory be present. However, it is stated that recruitment into both
groups was 'consecutive' and that the control group was recruited
using the same inclusion criteria, therefore selection should not have
been influenced.
2.4. Do start of follow-up and
start of intervention coincide
for most participants?
Y From the information provided, it appears that the intervention was
started on recruitment to the study. The control (standard epilepsy
care) would have started before the study
'Risk of bias' judgement Low The control group was added to the study design 18 months after the
start of the study, therefore characteristics and outcomes of
participants within the intervention group who had completed the 6-
month study period would have been known and a period effect could
in theory be present. However, it is stated that recruitment into both
groups was "consecutive" and that the control group was recruited
using the same inclusion criteria, therefore selection should not have
been influenced.








Bias in classification of interventions
3.1 Were intervention groups
clearly defined?
Y Intervention group receive SUDEP information plus standard epilepsy
care and control group receive standard epilepsy care only
3.2 Was the information used
to define intervention groups
recorded at the start of the
intervention?
PY The control group was added to the study design 18 months after the
start of the study, therefore characteristics and outcomes of
participants within the intervention group who had completed the 6-
month study period would have been known.
It is unclear whether both groups (intervention and control) or only
the control group were recruited to following the addition of the
control group (i.e. whether the intervention groups were defined by
the time point).
3.3 Could classification of
intervention status have been
affected by knowledge of the
outcome or risk of the
outcome?
PY The control group was added to the study design 18 months after the
start of the study, therefore characteristics and outcomes of
participants within the intervention group who had completed the 6-
month study period would have been known.
It is unclear whether both groups (intervention and control) or only
the control group were recruited to following the addition of the
control group (i.e. whether the intervention groups were defined by
the time point).
'Risk of bias' judgement Moderate The control group was added to the study design 18 months after the
start of the study, therefore characteristics and outcomes of
participants within the intervention group who had completed the 6-
month study period would have been known. It is unclear whether
both groups (intervention and control) or only the control group were
recruited to following the addition of the control group (i.e. whether
the intervention groups were defined by the time point).
 
Bias due to deviations from intended interventions (aim for this study is to assess the effect of assignment to
intervention)
4.1. Were there deviations
from the intended
intervention beyond what
would be expected in usual
practice?
Y Both groups received 'standard epilepsy care' but it was not described
what was involved in this control intervention and whether this
intervention was given consistently across all participants.
Within the intervention group, all participants were given detailed
information on SUDEP at baseline, delivered by a senior doctor and an
epilepsy expert.
However, only participants who did not have depression and anxiety
detected at baseline received a 'reinforcement' intervention at
subsequent clinical visits, therefore intervention was delivered
inconsistently.
4.2. If Y/PY to 4.1: Were these
deviations from intended
intervention unbalanced
between groups and likely to
have affected the outcome?
Y / PY / PN
/ N / NI /
NA
Unclear whether there was any imbalance in the 'standard epilepsy
care' received by both groups as no information on this intervention
is provided.
Participants for whom depression and anxiety was detected in the
intervention group did not receive 'reinforcement' SUDEP information
at subsequent clinics. As 1 of the aims of the study was examine the
impact of providing the SUDEP information on anxiety and
depression, this deviation will have directly impacted upon the
outcome.







'Risk of bias' judgement Critical Participants for whom depression and anxiety was detected in the
intervention group did not receive 'reinforcement' SUDEP information
at subsequent clinics. As 1 of the aims of the study was examine the
impact of providing the SUDEP information on anxiety and
depression, this deviation will have directly impacted upon the
outcome.
 
Bias due to missing data
5.1 Were outcome data
available for all, or nearly all,
participants?
Y Outcome data available for 116 out of 121 participants in the
intervention group (96%) and 106 out of 110 participants in the
control group (96%)
5.2 Were participants
excluded due to missing data
on intervention status?
PN It appears that the few missing patients were lost to follow-up or did
not complete the outcome measures to be included in analysis at the
end of the 6-month study period
5.3 Were participants
excluded due to missing data
on other variables needed for
the analysis?
PN It appears that the few missing patients were lost to follow-up or did
not complete all of the outcome measures to be included in analysis
at the end of the 6-month study period
'Risk of bias' judgement Low Outcome data available for 96% of recruited participants in the
intervention and control groups and it appears that the few missing
patients were lost to follow-up or did not complete all of the outcome
measures to be included in analysis at the end of the 6-month study
period
 
Bias in measurement of outcomes
6.1 Could the outcome
measure have been
influenced by knowledge of
the intervention received?
Y Participants and personnel involved in the study would have been
aware of their intervention status and all outcomes measures
collected are subjective
6.2 Were outcome assessors
unaware of the intervention
received by study
participants?
NI Aside from participants who completed questionnaires for outcome
measures and were aware of their intervention status, it is unclear
who other outcome assessors were (e.g. individuals conducting
statistical analysis) and if any of these outcome assessors were
blinded




PY Questionnaires were administered to all participants in the
intervention and control groups, no apparent differences in the
outcome assessment
6.4 Were any systematic
errors in measurement of the
outcome unrelated to
intervention received?
PN It is possible that questionnaires could have been completed
incorrectly which would have impacted on the measurement of
outcomes but no evidence that this occurred systematically in the
study
'Risk of bias' judgement Moderate Outcomes of the study were subjective and measured by
questionnaires administered directly to participants. As participants
would have been aware of their intervention status when completing
the questionnaires, their intervention status may have influenced
their responses
 
Bias in selection of the reported result
Is the reported effect estimate likely to be selected, on the basis of the results, from...







7.1. ... multiple outcome
measurements within the
outcome domain?
PN It appears that outcomes have been measured according to the
validated questionnaires used within the studies, no evidence that
multiple outcome measurements have been made
7.2 ...multiple analyses of the
intervention-outcome
relationship?
PY Within-group analyses (pre-test/post-test differences in the
intervention and control group respectively) only are conducted for
most outcomes.
A between-group (intervention vs control group) analysis is reported
only for the primary outcome and it is unclear why such an analysis is
not reported for the secondary outcomes
7.3 ...different subgroups? Y A regression analysis is performed to examine which characteristics
'predictors of adherence' in the subgroup of participants with
improved adherence only which is not an appropriate analysis
'Risk of bias' judgement Critical Mostly within-group analyses only are reported and no between-
group analyses are reported for the secondary outcomes. A
regression analysis is performed to examine which characteristics
'predictors of adherence' in the subgroup of participants with
improved adherence only which is not an appropriate analysis
Footnotes





Bias due to confounding
1.1 Is there potential for
confounding of the effect of
intervention in this study?
Y Aim of the study was to explore variables that may influence the
factors associated with SUDEP. The 'intervention' of interest to us is
1 of those variables, so confounding is inevitable
1.2. If Y or PY to 1.1 Was the
analysis based on splitting




Case-control study, cases and controls were retrospectively
examined over the same period of time (1987 to 2014).
1.4. Did the authors use an
appropriate analysis method
that adjusted for all the
critically important confounding
domains?
PY Multivariable logistic regression, which includes grade of
supervision and number of nocturnal convulsive seizures. No other
potential confounding variables appear to be included in the model
but demographics and clinical characteristics of cases and controls
are fairly similar other than frequency of convulsive seizures which
seems to be the most important confounding factor therefore
analysis may be sufficient.
1.5. If Y or PY to 1.4: Were
confounding domains that were
adjusted for measured validly
and reliably by the variables
available in this study?
PY Data extracted from records of the epilepsy residential facilities
and medical records. Probably fairly accurate but some data is
missing for seizure variables and nocturnal supervision
1.6. Did the authors control for
any post- intervention variables
that could have been affected
by the intervention?
PN Intervention is given over a period of time, and variables are also
measured over a period of time with probable overlap
1.7. Did the authors use an
appropriate analysis method





Case-control study, cases and controls were examined over the
same period of time in the same residential facilities (date of death
of SUDEP cases used as an index date for matching cases).






'Risk of bias' judgement Moderate The objective of the study means that confounding is inevitable,
however from the information available, it seems that an
appropriate adjusted analysis was performed
 
Bias in selection of participants into the study
2.1. Was selection of
participants into the study (or
into the analysis) based on
participant characteristics
observed after the start of
intervention?
N
Case-control study, therefore selection was based on outcome
(SUDEP or no SUDEP), not based on any participants characteristics
and not related to the intervention
2.4 Do start of follow-up and
start of intervention coincide for
most participants?
PN
Cases and controls are examined over a fixed period (1987 to
2014) and it is not stated when any interventions were started for
the cases and controls. It is unlikely that interventions were started
at the beginning of the time period of interest for most
participants
2.5 If N or PN to 2.4 Were
adjustment techniques used
that are likely to correct for the
presence of selection biases?
PN Unclear exactly how controls were selected from the residential
facilities, it is only stated that the controls were matched. It is also
unclear how many deaths with reviewed to result in 60 SUDEP
cases and unclear if any adjustment was performed to correct for
selection bias
'Risk of bias' judgement Moderate Unclear how many participants were reviewed when establishing
SUDEP cases and exactly how matched controls were selected from
the residential facilities. Unclear if any selection bias could have
been present
 
Bias in classification of interventions
3.1 Were intervention groups
clearly defined?
PY  
Clear definitions of the grades of interventions and number of
participants in each 'grade' group in the cases and controls clearly
defined but intervention available for only around 80% of cases and
controls and not explicitly stated why 20% of cases and controls
are not included in analyses (e.g. due to missing data for grade of
intervention).
3.2 Was the information used to
define intervention groups
recorded at the start of the
intervention?
N Likely that the 'grades' of intervention were defined for the
purposes of this study. Level of nocturnal intervention within the
residential facilities changed over the period of time of the study. It
is unclear whether cases and controls could have been classified as
a number of 'grades' at different points during the study and how
the 'grade' used in the analysis was determined.
3.3 Could classification of
intervention status have been
affected by knowledge of the
outcome or risk of the
outcome?
PN It is likely that nocturnal supervision was recorded for all residents
of the facilities, regardless of case or control status, however the
level of detail recorded and therefore the grade of intervention
classified may have been greater for individuals who died than
those who did not.
'Risk of bias' judgement Serious Likely that the 'grades of intervention' were defined for this study
rather than at the start of the intervention, unclear whether the
grades could have changed over time and it is possible that
classification of the grade of intervention may have been affected
by knowledge of case or control status.
 
Bias due to deviations from intended interventions (aim for this study is to assess the effect of starting and
adhering to intervention)






4.3. Were important co-
interventions balanced across
intervention groups?
N Convulsive seizure frequency and intelligence quotient were not
balanced across cases and controls.




No information given but possible that intervention could be
disrupted (e.g. person supervised leaves the room) or devices fail.
It is also unclear whether cases and controls could have been
classified as a number of 'grades' at different points during the
study and how the 'grade' used in the analysis was determined.
4.5. Did study participants
adhere to the assigned
intervention regimen?
NI
No information given regarding adherence or consistency of the
interventions
4.6. If N or PN to 4.3, 4.4 or 4.5
Was an appropriate analysis
used to estimate the effect of
starting and adhering to the
intervention?
N
Adherence to or consistency of the intervention is not mentioned
or taken account of in analysis
'Risk of bias' judgement Serious Intervention of interest to us was not necessarily intended to be
the only 'intervention' in the study. No information is given
regarding adherence to the intervention, the consistency of the
intervention and whether the 'grade' of the intervention could have
changed over time and co-interventions may have been present
 
Bias due to missing data
5.1 Were outcome data available
for all, or nearly all,
participants?
Y Participants selected based on outcome status (case-control study)
5.2 Were participants excluded
due to missing data on
intervention status?
Y 20% of cases and controls were excluded from analysis due to
missing data on 'grade' of intervention
5.3 Were participants excluded
due to missing data on other
variables needed for the
analysis?
Y Data also missing for cases and controls for other variables which
would have lead to exclusions from analysis
5.4 If PN/N to 5.1, or Y/PY to
5.2 or 5.3: Are the proportion of
participants and reasons for
missing data similar across
cases and controls?
PY Proportions of missing data similar across cases and controls but
no reasons given for missing data.
5.5 If PN/N to 5.1, or Y/PY to
5.2 or 5.3: Is there evidence
that results were robust to the
presence of missing data?
PY No analyses performed to account for missing data, however
amount of missing data is relatively small and balanced across
cases and controls, therefore unlikely conclusions would have been
changed by this missing data
'Risk of bias' judgement Moderate Around 20% of included cases and controls were excluded from
analysis due to missing data but as the amount of missing data is
relatively small and balanced across cases and controls, therefore
unlikely conclusions would have been changed by this missing data
 
Bias in measurement of outcomes
6.1 Could the outcome measure
have been influenced by
knowledge of the intervention
received?
N Cases were those who had experienced SUDEP, controls had not
experienced SUDEP






6.2 Were outcome assessors
aware of the intervention
received by study participants?
PN It is likely that cases and controls were established first and then
variable information to classify the information status was
extracted afterwards but not completely clear.





It is likely that cases and controls were established first and then
variable information to classify the information status was
extracted afterwards but not completely clear.
6.4 Were any systematic errors
in measurement of the outcome
related to intervention received?
PN
Cases were those who had experienced SUDEP, controls had not
experienced SUDEP, therefore very unlikely that any errors related
to measurement of the outcome occurred. However it is not clear
exactly how the cases and controls were selected into the study
from all residents
'Risk of bias' judgement Moderate Objective outcome measurement, but unclear exactly how cases
and controls were selected into the study and whether intervention
status was determined after outcome status
 
Bias in selection of the reported result




PN A single and clearly defined outcome, SUDEP or no SUDEP but
unclear exactly how the cases and controls were selected
7.2 ...multiple analyses of the
intervention-outcome
relationship?
PN Multivariable analysis performed with 2 variables, unlikely other
analyses were performed. Unclear if different classifications of
'grade of intervention' could have been analysed
7.3 ...different subgroups? N No subgroups reported
'Risk of bias' judgement Moderate Results for 1 multivariable model reported, unclear if results would
have been different for other multivariable models or if 'grade of
intervention' could have been classified differently.
Footnotes
Abbreviations: Y: yes; PY: probably yes; PN: probably no; N: no; NI: no information
AEDs: antiepileptic drugs
SUDEP: Sudden Unexpected Death in Epilepsy
6 Grades of nocturnal supervision and association with SUDEP in van der Lende 2018
Nocturnal SupervisionSUDEP casesControls Odds Ratio (95% CI)a
Grade 1 28/48 (58%) 84/163 (52%)0.73 (0.15 to 3.46), P = 0.693
Grade 2 16/48 (33%) 73/163 (45%)0.37 (0.08 to 1.83), P = 0.225
Grade 3 4/48 (8%) 6/163 (4%) Reference
Footnotes
Abbreviations: CI: confidence interval; P: P value; SUDEP: Sudden Unexpected Death in Epilepsy
a. Odds ratios calculated from a multivariable logistic regression model with grade of supervision corrected for
epilepsy severity (number of nocturnal convulsive seizures).
7 Within-group changes from baseline to 6 months in depression, anxiety and quality of life in
Radhakrishnan 2018
Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP)
41 / 54








SUDEP information1162.99 (2.38 to 3.59) 2.70 (2.14 to 3.26) 0.105
Control 1063.17 (2.53 to 3.81) 2.82 (2.24 to 3.40) 0.080
Anxiety (HAM-A)
SUDEP information1167.19 (6.16 to 8.21) 6.68 (5.71 to 7.65) 0.119
Control 1066.76 (5.88 to 7.64) 6.21 (5.31 to 7.11) 0.387
Quality of life (QOLIE-31)a
SUDEP information11168.06 (65.35 to 70.77)68.05 (65.70 to 70.40)0.991
Control 10469.97 (67.59 to 72.34)68.19 (65.85 to 70.53)0.161
Footnotes
a. Results were not reported for the 7 participants (5 in the SUDEP information group and 2 in the control group
who completed the QOLIE-AD-48)
CI: Confidence interval; HAM-A: Hamilton Anxiety Rating Scale; PHQ-9: Patient Health Questionnaire; QOLIE-31:
Quality of Life in Epilepsy-31; QOLIE-AD-48: Quality of life in Epilepsy for Adolescents; SUDEP: Sudden
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Data and analyses 
1 Use of interventions compared to no interventions to prevent SUDEP
Outcome or Subgroup Studies ParticipantsStatistical Method Effect Estimate
1.1 Nocturnal supervision
compared to no supervision 1   Odds Ratio(M-H, Fixed, 95% CI) No totals
1.2 Nocturnal supervision
compared to no supervision
(odds ratio only available)
1   Odds Ratio(IV, Fixed, 95% CI) No totals
1.3 Additional nocturnal
supervision compared to no
additional nocturnal supervision
1   Odds Ratio(M-H, Fixed, 95% CI) No totals
1.4 Special precautions
compared to no special
precautions
1   Odds Ratio(M-H, Fixed, 95% CI) No totals
Figures
Figure 1




Sources of support 
Internal sources
No sources of support provided
External sources
National Institute for Health Research (NIHR), UK
Feedback 
Appendices 
1 CRS Web search strategy
1. SUDEP AND INSEGMENT
2. MeSH DESCRIPTOR Death, Sudden Explode All AND INSEGMENT
3. (sudden or unexp*) NEAR4 death AND INSEGMENT
4. #2 OR #3
5. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND INSEGMENT
6. MESH DESCRIPTOR Seizures EXPLODE ALL AND INSEGMENT
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7. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND INSEGMENT
8. #5 OR #6 OR #7 AND INSEGMENT
9. #4 AND #8
10. #1 OR #9
11. SUDEP AND CENTRAL:TARGET
12. MeSH DESCRIPTOR Death, Sudden Explode All AND CENTRAL:TARGET
13. (sudden or unexp*) NEAR4 death AND CENTRAL:TARGET
14. #12 OR #13 AND CENTRAL:TARGET
15. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
16. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
17. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
18. #15 OR #16 OR #17 AND CENTRAL:TARGET
19. #14 AND #18 AND CENTRAL:TARGET
20. #11 OR #19 AND CENTRAL:TARGET
21. #10 OR #20
2 MEDLINE search strategy
We have based this search strategy on the Cochrane Highly Sensitive Search Strategy for identifying
randomised trials (Lefebvre 2011).
1. SUDEP.tw.
2. exp Death, Sudden/
3. ((sudden or unexp$) adj4 death).tw.
4. 2 or 3
5. exp Epilepsy/ or epilep$.tw.
6. exp Seizures/
7. (seizure$ or convuls$).ti.
8. 5 or 6 or 7
9. exp *Pre-Eclampsia/ or exp *Eclampsia/
10. 8 not 9
11. 1 or (4 and 10)
12. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or
placebo or randomly).ab.
13. clinical trials as topic.sh.
14. trial.ti.
15. 12 or 13 or 14
16. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv or
comparative study or evaluation studies or multicenter study or observational study or validation studies).pt.
17. ((clinical or comparative or controlled or evaluation or multicenter or multi-center or multicentre or multi-
centre or validation) adj3 (study or studies or trial?)).tw,hw.
18. epidemiologic studies/ or exp case-control studies/ or exp cohort studies/ or exp controlled before-after
studies/ or exp cross-sectional studies/ or exp historically controlled study/ or exp interrupted time series
analysis/
19. (cohort$ or (case$ adj3 (comparison$ or control$ or series))).tw,hw.
20. epidemiologic methods/
21. limit 20 to yr=1966-1989
22. (("before and after" or "before-and-after" or case$ or cross?section$ or "cross section$" or "follow up" or
"follow-up" or longitudinal or observation$ or prospective or "record-linkage" or "record linkage" or retrospective
or "time-series" or "time series") adj2 (analy$ or investigat$ or method or procedure or study or studies or
trial?)).tw,hw.
23. ("quasi-experiment$" or quasiexperiment$ or "quasi experiment$" or "quasi random$" or "quasi-random$" or
quasirandom$ or "quasi control$" or "quasi-control$" or quasicontrol$).ti,ab,hw.
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24. (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or
twelve or month$ or hour? or day? or "more than")).ab.
25. (control adj3 (area or cohort? or compare? or condition or design or group? or intervention? or participant? or
study)).ab. not (controlled clinical trial or randomized controlled trial).pt.
26. (control year? or experimental year? or control period? or experimental period?).ti,ab.
27. ((strategy or strategies) adj2 (improv$ or education$)).ti,ab.
28. ((single or doubl$ or tripl$ or treb$) adj3 (blind$ or mask$)).tw.
29. ("4 arm" or "four arm").tw,hw.
30. 16 or 17 or 18 or 19 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31. 15 or 30
32. exp animals/ not humans.sh.
33. 31 not 32
34. 33 not case reports.pt.
35. 11 and 34
36. remove duplicates from 35
3 SCOPUS search strategy
((((TITLE-ABS-KEY(SUDEP OR "Sudden Unexplained Death in Epilepsy" OR "Sudden Unexpected Death in Epilepsy"))
OR ((TITLE-ABS-KEY(death W/4 (sudden OR unexp*))) AND ((TITLE-ABS-KEY(epilep* OR "infantile spasm" OR "ring
chromosome 20" OR "R20" OR "myoclonic encephalopathy" OR "pyridoxine dependency") OR (TITLE-ABS-
KEY(syndrome) W/2 (aicardi OR angelman OR doose OR dravet OR janz OR jeavons OR "landau kleffner" OR
"lennox gastaut" OR ohtahara OR panayiotopoulos OR rasmussen OR rett OR "sturge weber" OR tassinari OR
"unverricht lundborg" OR west)) OR TITLE(seizure OR convuls*) OR (TITLE-ABS-KEY(lafora*) W/4 (disease OR
epilep*) AND NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR canine)))) AND NOT (TITLE(*eclampsia) OR
INDEXTERMS(*eclampsia))))) AND ((TITLE-ABS((randomiz* OR randomis* OR controlled OR placebo OR blind* OR
unblind* OR "parallel group" OR crossover OR "cross over" OR cluster OR "head to head") W/4 (analy* OR
investigat* OR method OR procedure OR study OR studies OR trial))) OR ((( TITLE-ABS(("before and after" OR
cohort OR comparative OR "cross section*" OR "follow up" OR longitudinal OR multicenter OR observation* OR
prospective OR quasicontrol* OR "quasi control*" OR quasiexperiment* or "quasi experiment*" OR quasirandom*
OR "quasi random*" OR "record linkage" OR retrospective OR "time series") W/4 (analy* OR investigat* OR method
OR procedure OR study OR studies OR trial))) OR (TITLE-ABS(case* W/3 (comparison* OR control* OR series))) OR
(TITLE-ABS((clinical OR epidemiologic OR evaluation OR validation) PRE/3 (study OR studies OR trial))) OR
(ABS("time points" W/3 (over OR multiple OR three OR four OR five OR six OR seven OR eight OR nine OR ten OR
eleven OR twelve OR month OR hour OR day OR "more than"))) OR (ABS(control W/3 (area OR cohort OR compare*
OR condition OR design OR group OR intervention OR participant OR study))) OR (TITLE-ABS("control year" OR
"experimental year" OR "control period" OR "experimental period")) OR (TITLE-ABS((strategy OR strategies) W/2
(improv* OR education*)))) OR (TITLE-ABS-KEY((single OR doubl* OR tripl* OR treb*) PRE/3 (blind* OR mask*)))
OR (TITLE-ABS-KEY("4 arm" OR "four arm"))))) AND NOT (TITLE(animal* OR mouse OR mice OR rat OR dog OR
canine) AND NOT TITLE(human* OR patient OR child* OR infant* OR adolescen* OR adult OR elderly OR man OR
men OR male OR wom?n OR female))) AND NOT (TITLE(case PRE/0 (report OR study OR studies)))
4 PsycINFO search strategy
S22 S6 AND S21
S21 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20
S20 "4 arm" OR "four arm"
S19 (single OR doubl* OR tripl* OR treb*) W3 (blind* OR mask*)
S18 AB ((strategy OR strategies) W2 (improv* OR education*))
S17 TI ((strategy OR strategies) W2 (improv* OR education*))
S16 AB ("control year" OR "experimental year" OR "control period" OR "experimental period")
S15 TI ("control year" OR "experimental year" OR "control period" OR "experimental period")
S14 AB (control W3 (area OR cohort OR compare* OR condition OR design OR group OR intervention OR
participant OR study))
S13 AB ("time points" W3 (over OR multiple OR three OR four OR five OR six OR seven OR eight OR nine OR ten
OR eleven OR twelve OR month OR hour OR day OR "more than"))
S12 AB ((clinical OR epidemiologic OR evaluation OR validation) W2 (study OR studies OR trial))
S11 TI ((clinical OR epidemiologic OR evaluation OR validation) W2 (study OR studies OR trial))
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S10 TI ( case* W3 (comparison* OR control* OR series) ) OR AB ( case* W3 (comparison* OR control* OR series) )
S9 AB (("before and after" OR cohort OR comparative OR controlled OR "cross section*" OR "follow up" OR
longitudinal OR multicenter OR observation* OR prospective OR quasicontrol* OR quasi-control* OR
quasiexperiment* or quasi-experiment* OR quasirandom* OR "record linkage" OR retrospective OR "time series")
W3 (analy* OR investigat* OR method OR procedure OR study OR studies OR trial))
S8 TI (("before and after" OR cohort OR comparative OR controlled OR "cross section*" OR "follow up" OR
longitudinal OR multicenter OR observation* OR prospective OR quasicontrol* OR quasi-control* OR
quasiexperiment* or quasi-experiment* OR quasirandom* OR "record linkage" OR retrospective OR "time series")
W3 (analy* OR investigat* OR method OR procedure OR study OR studies OR trial))
S7 TI ( (randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group" OR
crossover OR cross-over OR cluster OR "head to head") N2 (analy* OR method OR procedure OR study OR studies
OR trial) ) OR AB ( (randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group"
OR crossover OR cross-over OR cluster OR "head to head") N2 (analy* OR method OR procedure OR study OR
studies OR trial) )
S6 S1 OR (S2 AND S5)
S5 S3 OR S4
S4 MM "Epilepsy" OR MM "Epileptic Seizures" OR MM "Lennox Gastaut Syndrome" OR MM "Grand Mal Seizures" OR
MM "Petit Mal Seizures" OR MM "Status Epilepticus"
S3 epilep* OR seizure*
S2 (sudden or unexp*) N4 death
S1 "Sudden Unexplained Death in Epilepsy" OR "Sudden Unexpected Death in Epilepsy" OR SUDEP
5 CINAHL search strategy
S24 S8 AND S23
S23 S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22
S22 "4 arm" OR "four arm"
S21 (single OR doubl* OR tripl* OR treb*) W3 (blind* OR mask*)
S20 AB ((strategy OR strategies) W2 (improv* OR education*))
S19 TI ((strategy OR strategies) W2 (improv* OR education*))
S18 AB ("control year" OR "experimental year" OR "control period" OR "experimental period")
S17 TI ("control year" OR "experimental year" OR "control period" OR "experimental period")
S16 AB (control W3 (area OR cohort OR compare* OR condition OR design OR group OR intervention OR
participant OR study))
S15 AB ("time points" W3 (over OR multiple OR three OR four OR five OR six OR seven OR eight OR nine OR ten
OR eleven OR twelve OR month OR hour OR day OR "more than"))
S14 AB ((clinical OR epidemiologic OR evaluation OR validation) W2 (study OR studies OR trial))
S13 TI ((clinical OR epidemiologic OR evaluation OR validation) W2 (study OR studies OR trial))
S12 TI ( case* W3 (comparison* OR control* OR series) ) OR AB ( case* W3 (comparison* OR control* OR series) )
S11 AB (("before and after" OR cohort OR comparative OR controlled OR "cross section*" OR "follow up" OR
longitudinal OR multicenter OR observation* OR prospective OR quasicontrol* OR quasi-control* OR
quasiexperiment* or quasi-experiment* OR quasirandom* OR "record linkage" OR retrospective OR "time series")
W3 (analy* OR investigat* OR method OR procedure OR study OR studies OR trial))
S10 TI (("before and after" OR cohort OR comparative OR controlled OR "cross section*" OR "follow up" OR
longitudinal OR multicenter OR observation* OR prospective OR quasicontrol* OR quasi-control* OR
quasiexperiment* or quasi-experiment* OR quasirandom* OR "record linkage" OR retrospective OR "time series")
W3 (analy* OR investigat* OR method OR procedure OR study OR studies OR trial))
S9 TI ( (randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group" OR
crossover OR cross-over OR cluster OR "head to head") N2 (analy* OR method OR procedure OR study OR studies
OR trial) ) OR AB ( (randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group"
OR crossover OR cross-over OR cluster OR "head to head") N2 (analy* OR method OR procedure OR study OR
studies OR trial) )
S8 S1 OR (S4 AND S7)
S7 S5 OR S6
S6 MM ("Epilepsy+") OR (MM "Seizures")
S5 epilep* OR seizure*
Treatments for the prevention of Sudden Unexpected Death in Epilepsy (SUDEP)
51 / 54
S4 S2 OR S3
S3 (sudden or unexp*) N4 death
S2 (MH "Death, Sudden+")
S1 "Sudden Unexplained Death in Epilepsy" OR "Sudden Unexpected Death in Epilepsy" OR SUDEP
6 ClinicalTrials.gov search strategy
SUDEP OR (death AND (sudden OR unexplained OR unexpected)) | Epilepsy
7 ICTRP search strategy
SUDEP OR sudden AND death AND epilepsy OR unexp* AND death AND epilepsy
8 Signalling questions for the seven 'Risk of bias' domains of the ROBINS-I tool
Bias due to confounding
1.1 Is there potential for confounding of the effect of
intervention in this study?
If N/PN to 1.1: the study can be considered to be at low risk of
bias due to confounding and no further signalling questions
need be considered
If Y/PY to 1.1: determine whether there is a need to assess
time-varying confounding
Y/PY/PN/N
1.2. If Y or PY to 1.1: Was the analysis based on splitting
participants’ follow up time according to intervention received?
If N/PN to 1.2, answer questions relating to baseline
confounding (1.4 to 1.6) 
If Y/PY to 1.2, go to question 1.3.
Y/PY/PN/N/NI/NA
1.3 Were intervention discontinuations or switches likely to be
related to factors that are prognostic for the outcome?
If N/PN to 1.3, answer questions relating to baseline
confounding (1.4 to 1.6) 
If Y/PY to 1.3, answer questions relating to both baseline and
time-varying confounding (1.7 and 1.8)
Y/PY/PN/N/NI/NA
1.4. Did the authors use an appropriate analysis method that
controlled for all the important confounding domains?
Y/PY/PN/N/NI/NA
1.5. If Y or PY to 1.4: Were confounding domains that were
controlled for measured validly and reliably by the variables
available in this study?
Y/PY/PN/N/NI/NA
1.6. Did the authors control for any post- intervention variables
that could have been affected by the intervention?
Y/PY/PN/N/NI/NA
1.7. Did the authors use an appropriate analysis method that
controlled for all the important confounding domains and for
time-varying confounding?
Y/PY/PN/N/NI/NA
1.8. If Y or PY to 1.7: Were confounding domains that were
controlled for measured validly and reliably by the variables
available in this study?
Y/PY/PN/N/NI/NA
'Risk of bias' judgement Low/Moderate/Serious/Critical/NI





Bias in selection of participants into the study
2.1. Was selection of participants into the study (or into the
analysis) based on participant characteristics observed after the
start of intervention?
If N/PN to 2.1: go to 2.4
Y/PY/PN/N/NI
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2.2. If Y/PY to 2.1: Were the post- intervention variables that
influenced selection likely to be associated with intervention?
Y/PY/PN/N/NI/NA
2.3. If Y/PY to 2.2: Were the postintervention variables that
influenced selection likely to be influenced by the outcome or a
cause of the outcome?
Y/PY/PN/N/NI/NA
2.4. Do start of follow-up and start of intervention coincide for
most participants?
Y/PY/PN/N/NI
2.5. If Y/PY to 2.2 and 2.3, or N/PN to 2.4: Were adjustment
techniques used that are likely to correct for the presence of
selection biases?
Y/PY/PN/N/NI/NA
'Risk of bias' judgement Low/Moderate/Serious/Critical/NI
OPTIONAL 2.5: What is the predicted direction of bias due to





Bias in classification of interventions
3.1 Were intervention groups clearly defined? Y/PY/PN/N/NI
3.2 Was the information used to define intervention groups
recorded at the start of the intervention?
Y/PY/PN/N/NI
3.3 Could classification of intervention status have been
affected by knowledge of the outcome or risk of the outcome?
Y/PY/PN/N/NI
'Risk of bias' judgement Low/Moderate/Serious/Critical/NI
OPTIONAL 3.4: What is the predicted direction of bias due to





Bias due to deviations from intended interventions
If your aim for this study is to assess the effect of assignment to intervention, answer questions 4.1 and 4.2
If your aim for this study is to assess the effect of starting and adhering to intervention, answer questions 4.3 to
4.6
4.1. Were there deviations from the intended intervention
beyond what would be expected in usual practice?
Y/PY/PN/N/NI
4.2. If Y/PY to 4.1: Were these deviations from intended
intervention unbalanced between groups and likely to have
affected the outcome?
Y/PY/PN/N/NI/NA
4.3. Were important co-interventions balanced across
intervention groups?
Y/PY/PN/N/NI
4.4. Was the intervention implemented successfully for most
participants?
Y/PY/PN/N/NI
4.5. Did study participants adhere to the assigned intervention
regimen? Y/PY/PN/N/NI
4.6. If N/PN to 4.3, 4.4 or 4.5: Was an appropriate analysis used
to estimate the effect of starting and adhering to the
intervention?
Y/PY/PN/N/NI/NA
'Risk of bias' judgement Low/Moderate/Serious/Critical/NI
OPTIONAL 4.5: What is the predicted direction of bias due to





Bias due to missing data
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5.1 Were outcome data available for all, or nearly all,
participants?
Y/PY/PN/N/NI
5.2 Were participants excluded due to missing data on
intervention status?
Y/PY/PN/N/NI
5.3 Were participants excluded due to missing data on other
variables needed for the analysis?
Y/PY/PN/N/NI
5.4 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Are the proportion of
participants and reasons for missing data similar across
interventions?
Y/PY/PN/N/NI/NA
5.5 If PN/N to 5.1, or Y/PY to 5.2 or 5.3: Is there evidence that
results were robust to the presence of missing data?
Y/PY/PN/N/NI/NA
'Risk of bias' judgement Low/Moderate/Serious/Critical/NI






Bias in measurement of outcomes
6.1 Could the outcome measure have been influenced by
knowledge of the intervention received?
Y/PY/PN/N/NI
6.2 Were outcome assessors unaware of the intervention
received by study participants?
Y/PY/PN/N/NI
6.3 Were the methods of outcome assessment comparable
across intervention groups?
Y/PY/PN/N/NI
6.4 Were any systematic errors in measurement of the outcome
unrelated to intervention received?
Y/PY/PN/N/NI
'Risk of bias' judgement Low/Moderate/Serious/Critical/NI






Bias in selection of the reported result
Is the reported effect estimate likely to be selected, on the basis of the results, from...
7.1. ... multiple outcome measurements within the outcome
domain?
Y/PY/PN/N/NI
7.2 ...multiple analyses of the intervention-outcome
relationship?
Y/PY/PN/N/NI
7.3 ...different subgroups? Y/PY/PN/N/NI
'Risk of bias' judgement Low/Moderate/Serious/Critical/NI
OPTIONAL 7.4: What is the predicted direction of bias due to





Abbreviations: Y: yes; PY: probably yes; PN: probably no; N: no; NI: no information; NA: not applicable
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